Dual role of CD9 protein in mast cell activation by Machyna, Martin
Charles University in Prague 
Faculty of Science 
 
  
 
 
 
 
Dual Role of CD9 Protein in Mast 
Cell Activation 
 
Diploma thesis 
 
 
 
Martin Machyna 
Supervisor: RNDr. Petr Dráber, DrSc. 
 
Prague 2009 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
On the first place, I would like to thank to my supervisor Petr Dráber for his guidance and useful 
comments throughout my thesis and also to Daniel Smrž, who was helpful in indentifying CD9 as 
target of our monoclonal antibody. Next my gratitude belongs to Lukáš Kocanda, Dana 
Lorenčíková and Hana Mrázová who under leadership of Ľuba Dráberová prepared 2H9 
monoclonal antibody. 
My personal thanks also go to other members of our laboratory for their advices, kindness and 
friendly working atmosphere. And last but not least to my family and Zuzka Varadínová for their 
patience and morale support.  
  
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I proclaim that results presented in this diploma thesis were obtained by me independently under 
the leadership of my supervisor RNDr. Petr Dráber, DrSc. and other before mentioned members of 
our laboratory and all literature used was cited accordingly. 
 
Prague 30th of April 2009     …………………………………. 
  
4 
Abstract 
 Mast cells are well known effector cells in immune system. They have been implicated in such 
important processes as host defense against bacteria, toxins or parasites. However, in some cases 
they can develop improper reaction against harmless environmental antigens and thus causing 
allergies. It is therefore essential to understand signaling events that lead to activation of these cells 
in order to develop new treatment strategies. 
Newly prepared rat monoclonal antibody of IgG1 subtype raised against murine mast cells was 
characterized and found suitable for flow cytometry, immunoblotting and immunoprecipitation. 
Employing of optimized procedure for immunopurification in combination with mass spectrometry 
led to identification of its target cluster of differentiation (CD)9 protein. CD9 is a member of large 
protein family called tetraspanins. Functional studies showed that binding of this antibody to mast 
cells induced degranulation and early activation events such as increased tyrosine phosphorylation 
and enhanced levels of free cytoplasmic calcium. Interestingly, subsequent activation of these cells 
via antigen-mediated aggregation of the high-affinity IgE receptor (FcεRI) led to decreased 
degranulation, calcium response and tyrosine phosphorylation of several substrates.  Importantly, 
anti-CD9 antibody did not inhibit these responses in cells activated by thapsigargin, an inhibitor of 
endoplasmic reticulum calcium ATPases, indicating that downstream signaling events were not 
affected. The observed effects of the antibody were not caused by blocking binding of the antigen to 
FcεRI, coupling of CD9 to FcεRI by antibody nor by engagement of Fcγ receptors. 
 Involvement of CD9 in FcεRI-mediated activation events was supported by experiments 
employing cells with enhanced or decreased expression of CD9 by transfection with CD9 cDNA or 
silencing RNA, respectively. Cells with enhanced expression of CD9 exhibited more, while cells 
with decreased expression exhibited less anti-CD9-mediated effects. Surprisingly, degranulation of 
cells with decreased CD9 expression was comparable to wild-type cells which probably reflects of 
compensation by other tetraspanin family member. The combined data suggest that CD9 acts as a 
regulator of FcεRI-mediated activation. Antibody-mediated aggregation of CD9 leads to cell 
activation events. This might also activate negative feed-back mechanism which dampens FcεRI-
mediated activation resulting in impaired degranulation. 
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Abstrakt 
Žírne bunky sú známe efektorové bunky imunitného systemu. Ich účasť bola preukázaná v 
takých dôležitých procesoch ako sú obrana hostiteľa pred baktériami, toxínmi alebo parazitmi. 
Niekedy však môžu vytvárať neprimeranú reakciu proti neškodným antigénom v našom prostredí 
a spôsobovať tak alergie. Je práve preto vrcholne dôležité pochopiť signálne deje, ktoré vedú 
k aktivácii týchto buniek, za účelom vyvýjania nových stratégii liečby. 
Novovytvorená potkania monoklonálna protilátka izotypu IgG1, špecifická proti myším žírnym 
bunkám, bola charakterizovaná ako vhodná pre použitie v prietokovej cytometrii, imunoznačení 
a imunoprecipitácii. Použitie optimalizovaného postupu imunoizolácie v spojení s hmotnostnou 
spektrometriou umožnilo identifikovať CD9 ako jej cieľový proteín. CD9 je členom rozsiahlej 
rodiny nazývanej „tetraspanins“. Funkčné štúdie ukázali, že väzba tejto protilátky na žírne bunky 
spôsobila degranuláciu a aktiváciu včasných dejov ako sú zvýšená tyrozínová fosforylácia 
a zvýšená hladina voľného cytoplazmatického vápnika. Prekvapivé bolo zistenie že, následná 
aktivácia týchto buniek cez agregáciu FcεRI receptoru pomocou antigénu viedla naopak ku zníženej 
degranulácii, vápnikovej odpovedi a tyrozínovej fosforylácii niekoľkých substrátov. Anti-CD9 
protilátka však neinhibovala tieto bunkové odpovede, keď boli bunky aktivované thapsigarginom, 
inhibítorom vápnikových ATPáz v endoplazmatickom retikule, čo naznačuje, že neskoršie signálne 
deje neboli protilátkou ovplyvnené. Tieto efekty spôsobené protilátkou neboli spôsobené 
zabránením väzby antigénu na FcεRI, prepojením CD9 a FcεRI pomocou protilátky ani 
prekrýžením Fcγ receptorov. 
Účasť proteínu CD9 v procese aktivácie žírnych buniek cez FcεRI bola tiež podporená 
experimentami za využitia buniek so zníženou a zvýšenou expresiou CD9 pomocou transfekcie 
CD9 cDNA alebo „silencing RNA“. Bunky so zvýšenou expresiou CD9 vykazovali viac, zatiaľ čo 
bunky so zníženou expresiou vykazovali menej účinkov spôsobených anti-CD9. Degranulácia 
buniek so zníženou expresiou CD9 však bola porovnateľná s bunkami divokého typu, čo 
pravdepodobne odráža možnú kompenzáciu iným členom rodiny „tetraspanins“. Zhrnutím 
výsledkov sa ukazuje možnosť, že CD9 vystupuje ako regulátor aktivácie cez FcεRI receptor. 
Agregácia CD9 pomocou protilátky vedie k aktivácii buniek. To však môže aktivovať negatívne 
spätnoväzobné mechanizmy, ktoré následne tlmia FcεRI receptorovú aktiváciu, čo vyúsťuje do 
zníženej degranulácie. 
 
Kľúčové slová: CD9, tetraspanins, žírne bunky, signálna transdukcia, protilátka 
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List of abbreviations 
ATCC American Type Culture Collection 
BMMC Bone marrow-derived mast cell 
BSA Bovine serum albumin 
BSS-BSA Buffered salt saline containing 0.1% BSA 
Btk Burton’s tyrosine kinase 
CD Cluster of differentiation  
CD9KD Cells with downregulated CD9 expression 
CD9OE Cells with upregulated CD9 expression 
cDNA Complementary DNA 
CHAPS 3-[(3-chloamidopropyl)dimethyammonio]-1-propanesulfonate 
CM/PBS Complete medium diluted in PBS 
CMV Cytomegalovirus 
Csk C-terminal Src kinase 
CTMC Connective tissue mast cell 
DAG Diacylglycerol 
DMP Dimethyl pimelimidate 
DMSO Dimethyl sulfoxide 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
ER Endoplasmic reticulum 
Erk Extracellular signal-regulated protein kinase 
EtBr Ethidium bromide 
FCS Fetal calf serum 
FcεRI High-affinity IgE receptor 
Gab2 Grb2-associated binding protein 2 
GADS Grb2-related adaptor protein 
GEF Guanine nucleotide exchange factor 
GM-CSF Granulocyte macrophage colony-stimulating factor 
GPCR G protein-coupled receptor 
GPI Glycosyl-phosphatidylinositol 
Grb2 Growth factor receptor-bound protein 2 
HB-EGF Heparin-binding-epidermal growth factor 
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HRP Horseradish peroxidase 
IAA Iodoacetamide 
ICL Intracellular loop 
IL Interleukin 
IP3 Inositol (1,4,5) trisphosphate  
ITAM Immunoreceptor tyrosine-based activation motif 
JNK Jun N-terminal kinase 
kDa Kilodalton 
KO Knock-out 
LAT Linker of activated T cells 
LB Luria-Bertani 
LEL Large extracellular loop 
MALDI/FTMS Matrix-assisted laser desorption/ionization Fourier transform mass 
spectrometry 
ME 2-mercaptoethanol 
MHC-II Major histocompatibility complex II 
microHPLC-ESI-
MS/MS 
Microcapillary liquid chromatography in combination with 
electrospray ionization tandem mass spectrometry 
MMC Mucosal mast cell 
MMP-2 Matrix metalloproteinase 2 
MRP-1 Motility-related protein 1 
MS Mass spectrometry 
MUGlcU 4-Methylumbelliferyl β-D-Glucuronide 
NFAT Nuclear factor of activated T-cells 
NF-κB Nuclear factor-κB 
NI Non-infected 
non-OE Cells infected with empty pCDH vector 
non-siRNA Cells infected with non-silencing vector 
NP-40 Nonidet P-40 
NTAL Non-T cell activation linker 
PBS Phosphate buffered saline 
PI3K Phosphatidylinositol 3-Kinase 
PI4KII Phosphatidylinositol 4-kinase type II 
PIP2 Phosphatidylinositol (4,5)-bisphosphate  
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PIP3 Phosphatidylinositol (3,4,5)-trisphosphate 
PI-PLC Phosphatidylinositol-specific phospholipase C 
PKC Protein kinase C 
PLA2 Phospholipase A2 
PLCγ Phospholipase Cγ 
PMSF Phenylmethylsulphonyl fluoride 
RBL-2H3 2H3 subclone of RBL cell line 
SCF Stem cell factor 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SEL Small extracellular loop 
SH2 Src homology 2 domain 
Shc SH2 domain-containing transforming protein C 
shRNA Short hairpin ribonucleic acid 
SOC Super optimal broth with catabolite repression 
STIM1 Stromal interaction molecule 1 
Syk Spleen tyrosine kinase 
TCEP Tris(2-carboxyethyl)phosphine 
TE buffer Tris-EDTA buffer 
TEM Tetraspanin-enriched microdomain 
TGF Transforming growth factor 
TM Transmembrane domain 
TNF Tumor necrosis factor 
TNP 2,4,6-trinitrophenyl 
TNP-BSA TNP conjugated to BSA 
TNP-BSA-TRITC TNP-BSA conjugated to TRITC 
TNT Tris-NaCl-Tween buffer 
TRITC Tetramethyl Rhodamine Isothiocyanate 
VEGF Vascular endothelial growth factor 
WAVE Wiskott-Aldrich syndrome protein family verprolin-homologous 
protein 
WT Wild-type 
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1 Introduction 
Immune system is a complex cellular network whose main task is to establish integrity and 
homeostasis of host organism by mounting appropriate immune response. Many types of cells, both 
circulating in blood or residing in tissues, participate in this process and the efficiency of immune 
system is strictly dependent on their tight cooperation. Key feature is their ability to communicate 
either by direct cell-cell contact or remotely using cytokine network.  
Mast cells play indispensable role in immune system. They are leukocytes of myeloid cell linage 
which originate in bone marrow and their progenitors then enter blood stream to finish their 
development in different connective tissues. There they serve as defenders against multicellular 
parasites, bacteria and toxins but in certain cases they may react to harmless environmental antigens 
and thus causing allergies. It is therefore essential to understand processes that lead to their 
activation and release of effector molecules.  
Monoclonal antibodies turned out to be useful tools for identification of many new molecules 
and characterization of various protein functions. Even more, monoclonal antibodies are widely 
used as therapeutic agents to cure various severe diseases including cancer. Developing antibody 
which could negatively regulate mast cell activation and degranulation could have tremendous 
clinical impact.  
One of possible targets for such antibodies could be members of tetraspanin family because 
previous research with monoclonal antibodies raised against these proteins showed multiple 
inhibitory and also activatory effects on cells of hematopoietic origin including mast cells. 
Our laboratory has developed a panel of monoclonal antibodies which enabled us to clarify 
function of by then not well characterized proteins (e.g. Tec-21, PLSCR1). Recently, we generated 
a new panel of hybridomas producing monoclonal antibodies against bone marrow-derived mast 
cells (BMMCs) plasma membrane antigens. Next step was to select antibodies capable to modulate 
mast cell activation or recognizing proteins with yet unknown role in mast cell signaling.  
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2 Aims 
Aims of this diploma thesis were: 
 To characterize specificity of newly prepared monoclonal antibody recognizing an 
antigen on BMMCs (2H9). 
 To characterize properties of the target antigen recognized by 2H9 antibody. 
 To investigate effects of the antibody on mast cell degranulation.  
 To examine functional alterations in selected components of mast cell signaling 
pathways. 
 To generate cells with decreased or increased levels of the target antigen and compare 
their properties. 
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3 Literature review 
3.1 Tetraspanins 
3.1.1 Tetraspanin family 
Tetraspanins are large superfamily (Boucheix et al., 1991) of membrane type II proteins of 
molecular weight approximately 24–50 kilodaltons (kDa) consisting of approximately total 250 
amino acids (Hemler, 2001). They were discovered on preB and leukemic cells relatively long time 
ago (Kersey et al., 1981) but later they were described on other hematopoietic and non-
hematopoietic  cell types (Lanza et al., 1991; Mitamura et al., 1992). Genome sequences search 
revealed large number of tetraspanin members in other organisms from protozoan amoebae, plants 
(Huang et al., 2005), C. elegans (20 members) (Moribe et al., 2004), Drosophila (37 members) 
(Todres et al., 2000) to mammals (33 members) (Garcia-Espana et al., 2008). Recent attempt for 
phylogenetic analysis from 10 fully sequenced metazoan genomes divided tetraspanin superfamily 
into four major orthologous groups – the CD family, CD63 family, uroplakin family and RDS 
family (Garcia-Espana et al., 2008). It is now clear that this protein family is highly conserved and 
emerged early in the evolution. What more, tetraspanins are ubiquitously expressed in reasonably 
high numbers ranging from 30,000 to 100,000 molecules per cell (Hemler, 2005) and usually more 
than one tetraspanin gene is expressed in one cell type. Tarrant et al. estimate number of expressed 
tetraspanin genes in leukocytes to ≤ 20 (Tarrant et al., 2003). 
3.1.2 Structure of tetraspanins 
As can be deduced from their name tetraspanins cross plasma membrane four times facing both 
N-terminal and C-terminal ends to the cytosol. Four transmembrane domains (TM1-4) are linked by 
one very short intracellular loop (ICL) and two extracellular loops termed as small extracellular 
loop (SEL), joining TM1 and TM2, and large extracellular loop (LEL), joining TM3 with TM4. 
Although many other proteins contain four transmembrane domains, they are not members of 
tetraspanin family because they do not contain other tetraspanin-specific features. These are 
conserved cysteine residues in LEL and multiple conserved polar residues in transmembrane 
domains (Fig. 1).  
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Fig. 1 – Schematic structure of tetraspanins. 
Tetraspanins consist of four transmembrane domains (TM) containing conserved polar residues 
(green circles), short terminal ends, intracellular loop, small extracellular loop (SEL) and large 
extracellular loop (LEL). Relatively conserved and hydrophobic helices a, b and e are separated 
from hypervariable helices c and d by conserved cysteine residues (yellow circles). Juxtamembrane 
cysteines that can undergo palmitoylation are also shown (orange circles) (Levy and Shoham, 
2005b). 
Taken together, tetraspanin consist of five distinct functional regions (Stipp et al., 2003b). On 
the first place, it is LEL which is the most studied part of tetraspanins and also the only part whose 
structure was determined from crystal X-ray diffraction (Kitadokoro et al., 2001). Analysis of its 
structure revealed that it is formed by 5-helix bundle consisting of helixes A–E. Although LEL is 
not as conserved as TM parts, helices A, B and E possess a considerable amount of homology 
between tetraspanin members and their hydrophobic surface is believed to play role in 
homodimerization of tetraspanins. Helices C and D are hypervariable and contain more polar 
residues and mediate most of tetraspanin interactions with their protein partners. This is supported 
by localization of several specific interaction motifs – SFQ (173–175) in CD9 indispensable for 
sperm-egg fusion (Zhu et al., 2002), F186 in CD81 responsible for hepatitis virus C binding 
(Higginbottom et al., 2000a) and also QRD (194–196) motif in CD151 which is required for α3 and 
α6 integrins association (Kazarov et al., 2002). All these motifs overlap the same place in variable 
part of LEL. The most conserved part of LEL are cysteine residues organized to highly conserved 
motifs CCG and PXXC which are also one of the family specific markers. Totally four (CD9, 
CD81), six (CD151) or eight cysteine residues can be positioned within LEL capable of forming 2–
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4 disulphide bridges which stabilize overall bundle structure and separate variable part from 
conserved (see Fig. 1). According to these parameters, tetraspanins can be divided into three 
topological groups. Variable domain of group 1 tetraspanins (CD9, CD81) represents minimal 
topology comprising of two peptide stretches of variable domain and two disulphide bridges. Group 
2 has one of its peptide stretch divided into two by additional cysteine which forms third disulphide 
bridge. The most complex tetraspanins belong to group 3 and have inserted additional peptide 
stretches and pair of cysteines which forms another disulphide bridge. Therefore, it seems likely 
that more complex tetraspanins evolved from a basic topology by duplication of specific peptide 
stretches and disulphide insertions (Fig. 2) (Kitadokoro et al., 2002; Seigneuret et al., 2001). 
 
Fig. 2 – LEL topography of several tetraspanins 
Tetraspanins can be divided into three groups according to their LEL chain topology. Rectangles, 
arrows, and thinner lines represent helices, strands, and coil, respectively. Conserved parts are 
indicated in blue while variable domain is red. Cysteines and disulfide bridges are indicated in 
yellow. Glycine and proline residues of CCG and PXXC motifs are shown in green (Seigneuret et 
al., 2001). 
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Knowledge about 13–30 amino acid long SEL is very limited. It was reported that deletion of 
SEL reduces surface expression of truncated form of CD151 and thus it is required for optimal LEL 
expression (Masciopinto et al., 2001). SEL also contains putative site for N-glycosylation in CD9 
but it is currently unknown whether glycosylation in this position really occurs. However, one or 
more N-glycosylations of LEL is typical for almost all tetraspanins except CD9 and CD81. 
Transmembrane domains are the most conserved part of tetraspanin proteins. They contain 
highly polar residues which are also conserved and help to stabilize closely packed tertiary structure 
of these domains while hydrophobic residues contribute to tetraspanin-tetraspanin and tetraspanin-
non-tetraspanin partner interactions. Namely TM1-TM2 interface mediates interaction with other 
tetraspanins while second TM3-TM4 interface mediates heterotypic interaction with non-
tetraspanin partner (Kovalenko et al., 2005; Min et al., 2006). However presence of LEL is probably 
also important for homotypic tetraspanin-tetraspanin interactions because deletion of LEL disrupted 
homotypic interactions while interaction with other tetraspanins remained unchanged 
(Berditchevski et al., 2001). CD82 lacking TM1 was retained in endoplasmic reticulum (ER). 
However when mutant CD82 was co-expressed with TM1 peptide it was again able to reach PM. 
This suggests that transmembrane domains are also necessary for correct folding and transport of 
tetraspanins from ER to their destination (Cannon and Cresswell, 2001). 
Intracellular part of tetraspanins contains highly conserved cysteines which are palmitoylated in 
the process of protein maturation in Golgi. Tetraspanins first associate with their specific non-
tetraspanin partner in ER and later promoted by palmitoylation they tend to interact in tetraspanin-
tetraspanin fashion creating thus higher order structures (Tu et al., 2002). When cysteine residues 
are mutated in CD9 and CD151 proteins, intertetraspanin interactions are lost while association with 
non-tetraspanin partners remains untouched (Berditchevski et al., 2002; Charrin et al., 2002; Yang 
et al., 2002). Presence of excessive palmitoylation in tetraspanins may raise a question about 
localization of these proteins in lipid raft structures. Results suggest that palmitoylation is not 
sufficient signal for lipid rafts residency although certain fraction of tetraspanins is present in these 
structures. However similarly large fraction is not included and is independent of lipid rafts (Claas 
et al., 2001; Yashiro-Ohtani et al., 2000). 
Intracellular parts of tetraspanins, including ICL and terminal ends, are relatively conserved 
among species but are divergent between tetraspanin members. The most variable is C-terminal 
cytosolic tail which is believed to be related to specific function of each tetraspanin member. 
Indeed, specific motif GYEVM was discovered in CD63 C-terminal tail which localizes it to 
lysosomes (Rous et al., 2002). Other potential targeting motifs were predicted in various 
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tetraspanins but their significance was not tested. In addition it was proposed that tetraspanins that 
do not contain any targeting motif can be localized to various cellular compartments by interaction 
with tetraspanin that does contain one of these motifs (Stipp et al., 2003b). 
3.1.3 Tetraspanin interactions and tetraspanin-enriched microdomains (TEMs) 
As described in previous chapter, members of tetraspanin superfamily possess variety of 
interaction surfaces. Some of them serve for interaction with another tetraspanin molecule while 
others serve as specific site for non-tetraspanin partner molecule. Extensive research in the past 
decade produced huge amount of evidence of interactions between tetraspanins and their partners. 
Mentioning all of these results exceeds limits of this review and thus we refer to recent review 
articles which summarize most of the data (Hemler, 2008; Levy and Shoham, 2005a; Tarrant et al., 
2003).  
The most characteristic feature of the tetraspanin family members is their ability to interact with 
other partner molecules. From the result of the immunoprecipitation experiments, which were most 
frequently used to determine interaction partners, tetraspanin-partner interactions can be divided 
into three levels. 
 Primary interaction is between tetraspanin and its specific non-tetraspanin partner. This 
interaction is direct and robust and is maintained even in harsh non-ionic detergents like Triton X-
100 or nonidet P-40 (NP-40). Typical feature of these interactions is that single tetraspanin can form 
different partnerships in different cell types and their interaction is always stoichiometric. 
Secondary interactions take place between two molecules of tetraspanins and are mediated by 
hydrophobic surfaces of their TM domains. Therefore this might explain their low resistance to 
non-polar detergents such as Triton X-100. However they are no disrupted in milder detergents like 
Brij 96 or Brij 97 especially when divalent cations are present. As mentioned before these 
interactions are formed in Golgi and require functional palmitoylation of juxtamembrane cytosines 
to be formed. These interactions are also less robust and non-stoichiometric. 
Tertiary interactions are very weak and are retained only in mild detergents like 
3-[(3-chloamidopropyl)dimethyammonio]-1-propanesulfonate (CHAPS). They are indirect and link 
tetraspanins with partner of another tetraspanin by combined interaction (Boucheix and Rubinstein, 
2001; Levy and Shoham, 2005a; Tarrant et al., 2003). Taking into account this types of interactions 
and the fact that tetraspanins often co-immunoprecipitate with more than one tetraspanin led to 
creation of a concept of the tetraspanin web or later termed as TEMs (Rubinstein et al., 1996). 
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TEMs are believed to be highly dynamic structures the integrity of which is dependent on 
palmitoylation but are distinct and independent of lipid rafts. With respect to their function three 
models were proposed. First one suggests that TEMs act as transmembrane linkers bringing 
membrane protein partners laterally interacting with LEL and cytosolic signaling molecules 
associated with cytosolic tails to close proximity. This might cause extension of signal 
(Lammerding et al., 2003). Second proposes that TEMs help to cluster partner molecules and 
thereby increasing overall avidity for their ligand (Kropshofer et al., 2002). Finally, the last one 
proposes that TEMs might sequester their partner molecules from signaling machinery and thus 
dampen signal and prevent inappropriate response (Odintsova et al., 2003). 
3.1.4 CD9 is a member of tetraspanin family 
CD9, also known as motility-related protein 1 (MRP-1), DRAP27 or Tspan29, is one of the most 
studied tetraspanin members. This 24–25 kDa protein contains two disulphide bridges in LEL and 
putative glycosylation site in SEL. Its expression is extended but not ubiquitous. It comprises 
presence in skin, connective tissues, lungs, liver, gut, kidney, muscles, nervous system but also 
lymphoid tissues and cells – spleen, lymphnodes, lymphocytes, monocytes, platelets and 
megakaryocytes (Sincock et al., 1997). 
The most sever phenotype observed was reduced fertility of CD9 knock-out (KO) mice. This 
resulted from inability of CD9 KO mouse oocyte to fuse with a wild-type (WT) sperm, however 
binding of sperm and fusion of CD9 KO sperm with WT oocytes were unaffected (Kaji et al., 2000; 
Le Naour et al., 2000; Miyado et al., 2000). Reduced sperm-egg fusion was also observed in CD81 
KO mouse, but it is completely diminished in CD9 CD81 double-KO mouse (Rubinstein et al., 
2006). It was found that CD9 associates with EWI-2 and EWI-F (members of Ig superfamily) in 
oocyte membrane (Runge et al., 2007) and that EWI-2 membrane expression is significantly 
reduced in CD9 KO mouse (He et al., 2008). It is known that EWI proteins interact with ezrin-
radixin-moesin proteins and thereby linking CD9, as a part of TEMs, to actin cytoskeleton (Sala-
Valdes et al., 2006). EWI proteins also drive CD9 and CD81 localization to filopodia (Stipp et al., 
2003a) which might explain localization of CD9 in oocyte microvillar structures and how it 
regulates their length, thickness and density. Because microvilli morphology is altered in CD9 KO 
oocytes, one might suggest that microvilli could serve as docking site for close sperm-egg 
membrane contact facilitating their fusion (Runge et al., 2007). 
CD9 also plays a role in fusion of another cell types. Overexpression of CD9 caused increase in 
myoblast fusion (Tachibana and Hemler, 1999) and pretreatment with anti-CD9 antibody impaired 
osteoclast formation by inhibiting macrophages fusion (Tanio et al., 1999). Even more, CD9 is 
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responsible for canine distemper virus-induced cell-cell fusion but not cell-virus fusion (Singethan 
et al., 2006). In contrast, fusion of macrophages into multinucleated giant cells was increased in 
both CD9 and CD81 single-KO mice and even more CD9 and CD81 double-KO mouse 
spontaneously developed multinucleated giant cells and showed enhanced osteoclastogenesis. This 
resulted in kyphosis and osteopenia at later age (Takeda et al., 2008; Takeda et al., 2003). Taken 
this together, CD9 is implicated in regulation of various cell fusion events. 
 Thanks to extensive study of tetraspanins many interacting partners of CD9 were discovered. 
They include membrane structural proteins like EWI-2 and EWI-F, adhesion molecules like 
Claudin-1 (Kovalenko et al., 2007) and various subsets of integrins (α1β1, α2β1, α3β1, α4β1, α5β1, 
α6β1, α7β1, α6β4, αIIbβ3) (Berditchevski, 2001), signaling receptors and molecules c-kit (Anzai et 
al., 2002), G protein-coupled receptor (GPCR) (Little et al., 2004), membrane form of heparin-
binding-epidermal growth factor (HB-EGF) and transforming growth factor (TGF)-α (Nakamura et 
al., 1995; Shi et al., 2000) and major histocompatibility complex II (MHC-II) (Unternaehrer et al., 
2007). Even more, besides membrane protein partners, various intracellular signaling molecules 
were found to interact with CD9. These include phosphatidylinositol 4-Kinase type II (PI4KII) 
(Yauch and Hemler, 2000) and multiple forms of protein kinase C (PKC) (Zhang et al., 2001). 
However, CD9 can associate with other protein partners through indirect interactions in TEMs. 
These interactions confer CD9 ability to contribute to various cellular activities. 
CD9 was found downregulated in many tumors and surprisingly its expression inversely 
correlated with metastasis promotion. Low level of CD9 in cancer cells is maintained by promoter 
hypermethylation (Drucker et al., 2006) and this leads to activation of phosphatidylinositol 3-
Kinase  (PI3K) and Akt and thus increased integrin-mediated adhesion, higher motility, cell 
proliferation, survival and matrix metalloproteinase 2 (MMP-2) expression. All these effects are 
reversed by ectopic expression of CD9 or anti-CD9 antibody treatment (Ovalle et al., 2007; Saito et 
al., 2006). CD9 also plays a role in metastasis and transendotelial invasion, where its expression is 
locally restored at site of migration and even more CD9 on epithelial cells localizes to cell-cell 
contact area to facilitate migration (Longo et al., 2001; Sauer et al., 2003). This implicates that CD9 
may play a role of tumor suppressor. This is supported by trials of adenoviral CD9 gene delivery 
into tumors. These in vivo experiments showed that mice injected with CD9 gene lived longer and 
developed less metastasis (Miyake et al., 2000; Takeda et al., 2007). However, this is not always the 
case because overexpression of CD9 in human melanoma cells resulted in p38 and Jun N-terminal 
kinase (JNK) activation which led to phosphorylation of c-Jun and expression of MMP-2 (Hong et 
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al., 2005). Furthermore, CD9 CD81 double-KO mouse showed impaired macrophages motility 
leading to pulmonary emphysema (Takeda et al., 2008). 
Precise mechanism by which CD9 regulates cell migration, motility or adhesion is not clear but 
few possibilities emerge (Zoller, 2009). First is regulation of actin cytoskeleton by Wiskott-Aldrich 
syndrome protein family verprolin-homologous protein (WAVE) 2 which was shown to be 
downregulated in cells ectopically expressing CD9. WAVE2 is known to link upstream signals to 
ARP proteins which nucleates actin polymerization. However, way how CD9 regulates WAVE2 
expression is not clear (Huang et al., 2006). Second could be downregulation of Wnt1, Wnt2b and 
Wnt5a genes induced by CD9 expression. Although mechanism of this action is unknown, Wnt5a 
acts through Wnt-Ca2+ pathway which leads to actin reorganization and might modulate cell 
adhesion and motility (Huang et al., 2004). Third might be through interaction of CD9 with 
ganglioside GM3 which enables to associate with α3β1 integrin and translocates C-terminal Src 
kinase (Csk) to TEMs. This causes inhibition of Scr and Rac but activation of PI3K and Akt 
(Mitsuzuka et al., 2005). And finally as mentioned before, CD9 associates with members of EWI 
family which link CD9 to actin cytoskeleton and drives it to filopodia (Stipp et al., 2003a). 
Taking this together, CD9 plays important role in cell fusion, motility, adhesion, survival and 
possibly acts as tumor suppressor.  
3.2 Mast cells 
3.2.1 Mast cells overview 
Mast cells are leukocytes of myeloid origin initially identified by Ehrilich in 19th century. As a 
part of innate immunity, they play role in host defense against bacterial infections, viruses, venom 
toxins and multicellular parasites. However the major focus of current research still remains on their 
IgE-mediated hyperreativity to allergens. This is coupled with exhibiting allergic rhinitis, asthma, 
atopic dermatitis and several food allergies. It is therefore crucial to understand mast cell 
physiology and signaling events leading to their effector functions. 
3.2.2 Function and development 
Mast cells are derived from a hematopoietic stem cell. In contrast to related basophils, their 
committed precursors, characterized by c-kit+CD34+CD13+FcεRI- surface markers, leave bone 
marrow and finish their development in peripheral tissues such as skin, mucosa and airways 
(Kirshenbaum et al., 1999). Depending on local environment, they can maturate to different subsets 
like mucosal mast cells (MMCs) and connective tissue mast cells (CTMCs) which differ in their 
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granules content (Stevens et al., 1994). MMCs are T cell-dependent and do not maturate in the 
absence of inflammation while CTMCs are T cell-independent (Irani et al., 1987). However, both 
subtypes require interleukin (IL)-3 and stem cell factor (SCF) for their successful development as 
inferred from phenotype of mice carrying mutation in c-kit gene (Grimbaldeston et al., 2005). Mast 
cells with their lifespan ranging from weeks to months belong to long-lived cells and are also able 
to proliferate after finishing their maturation. 
Before being able to be activated by antigen, mast cells must bind antigen-specific  IgE antibody 
to the high-affinity receptor FcεRI on their surface. This process called sensitization is not just a 
passive event but sensitized cells increase their adhesion to extracellular matrix (Lam et al., 2003), 
cell proliferation and survival (Asai et al., 2001) and, importantly, expression of surface FcεRI 
(Yamaguchi et al., 1997) enabling further IgE binding. On encountering of specific multivalent 
antigen, mast cells became activated and release three types of effector molecules. Within first few 
minutes, which is called immediate reaction, they release prestored content of their cytosolic 
secretory granules such as biologically active amines (histamin and serotonin), proteoglycans, 
proteases, exoglycosidases and in some cases also tumor necrosis factor (TNF)-α. In late reaction 
which starts within 30 min, several arachidonic acids derivates (leukotrien C4 and prostaglandin D2) 
are synthesized followed by de novo protesynthesis of various cytokines, such as TNF-α, TGF-β, 
vascular endothelial growth factor (VEGF), interleukin IL-1, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-
13 and various chemokines (Marshall, 2004; Metcalfe et al., 1997). IL-4 was discovered as potent 
factor promoting antibody isotype switch to IgE and its increased production. This suggests possible 
positive feedback loop by which mast cells might enhance and maintain IgE-associated reaction 
driven by TH2 response (Yamaguchi et al., 1997). 
3.2.3 Structure of FcεRI receptor 
Selected effector functions of mast cells are mediated by FcεRI localized on their surface. FcεRI, 
together with T-cell receptor, B-cell receptor and other Fc receptors, belongs to immunoreceptor 
family which is characterized by absence of intrinsic kinase activity and presence of at least one 
immunoreceptor tyrosine-based activation motif (ITAM). This multimeric receptor comprises of 
one α subunit, one β subunit, which passes plasma membrane four times, and two single-spanning γ 
subunits linked by disulphide bridge. However, trimeric receptor αγ2 was described to be present on 
human monocytes, Langerhans cells, eosinophils and dendritic cells. All subunits are maintained in 
complex through electrostatic and hydrophobic non-covalent interactions (Kinet, 1999).  
The FcεRI α chain consists of short cytoplasmic tail, transmembrane region and two 
immunoglobulin-related domains which are N-glycosylated at seven sites. Glycosylation is required 
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for proper folding in ER but not for IgE binding (Letourneur et al., 1995). Extracellular part 
contains two binding sites for Cε3 domains of IgE and thus α subunit binds IgE in 1:1 stoichiometry 
(Garman et al., 2000). While cytoplasmic part does not confer any signaling activity and α subunit 
thus serves only for binding IgE, β and γ2 subunits play role in sensing of bound antigen and 
transduction of signal. They both contain ITAM motifs which are phosphorylated upon antigen-
mediated crosslinking of the receptor and then serve as binding sites for signaling molecules 
containing Src homology 2 (SH2) domains. Subunit β spans plasma membrane four times and 
serves as signal amplifier (Dombrowicz et al., 1998; Lin et al., 1996). However, homodimer 
consisting of two disulphide linked γ subunits is the main signaling unit of Fc receptor. Each γ 
subunit consists of transmembrane domain and cytosolic part containing single ITAM motif (Kinet, 
1999). 
3.2.4 Signaling pathways involved in mast cell activation 
After crosslinking of IgE-bound FcεRI receptor, cytosolic parts of β and γ2 chains containing 
ITAM motifs that have consensus sequence Y-x-x-(L/I/V)-x6-8-Y-x-x-(L/I/V) become 
phosphorylated. This is mediated by activity of Scr family kinase Lyn. The precise mechanism of 
these early steps remains elusive, however two hypotheses were proposed. First one suggests 
translocation of the receptor complex to lipid rafts upon antigen-mediated FcεRI aggregation where 
it is phosphorylated by resident Lyn kinase (Field et al., 1999). Another one is based on constitutive 
association of Lyn kinase minor fraction with Fc receptor and thus antigen-mediated aggregation 
leads to trans-phosphorylation of close receptors (Vonakis et al., 2001). Two phosphorylated 
tyrosines in β chain then serve as new docking sites for Lyn kinase while phosphorylated γ subunits 
harbor spleen tyrosine kinase (Syk) which is then activated by conformational change, 
autophosphorylation and/or phosphorylation by Lyn (Kimura et al., 1996).  In addition to this 
signal-initiating activity, Lyn also negatively regulates mast cell activation by inhibiting second Src 
family kinase Fyn. Fyn has positive role in mast cell signaling and it also associates with β chain 
and helps to active Syk kinase (Parravicini et al., 2002). Third Src family kinase is Hck is proposed 
to inhibit negative activity of Lyn kinase. Hck thus negatively regulates Lyn which negative 
regulates Fyn (Hong et al., 2007). Lyn also activates phosphatases and in this way also inhibits 
FcεRI signaling. 
Activated Syk and Src kinases then affect other downstream signaling proteins. First step in 
downstream signal transduction is phosphorylation of transmembrane adaptor proteins linker of 
activated T cells (LAT) and non-T cell activation linker (NTAL). BMMCs from NTAL KO mouse 
show augmented response to antigen challenge which led to conclusion that NTAL, in contrast to 
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LAT, is mainly negative regulator of mast cell signaling (Volná et al., 2004). Transmembrane 
adaptor proteins are special group of signaling molecules which lack intrinsic kinase or other 
enzymatic activities. Instead, they are bound to plasma membrane through their TM region and act 
as a meeting place for other signaling molecules by providing docking point for their interaction 
domains. Both LAT and NTAL contain docking site for growth factor receptor-bound protein 2 
(Grb2) which serves as cytosolic adaptor protein for SH2 domain-containing transforming protein C 
(Shc) and son of sevenless (SOS). SOS is a guanine nucleotide exchange factor (GEF) and 
facilitates exchange of GDP towards GTP in small G protein Ras. Ras-GTP then triggers cascade of 
phosphorylation events which lead to activation of extracellular signal-regulated protein kinase 
(Erk) (Jabril-Cuenod et al., 1996). This is followed by activation of phospholipase A2 (PLA2), 
which leads to eicosanoids production (Miura et al., 1999), and activation of activator protein 1 
(AP1) transcription factor which turns on transcription of cytokine genes (Gilfillan and Tkaczyk, 
2006). 
However, LAT but not NTAL holds binding sites for Grb2-related adaptor protein (GADS) and 
Phospholipase Cγ (PLCγ). GADS also interacts with SH2-domain-containig leukocyte protein of 65 
kDa (SLP76) which is phosphorylated by Lyn and Syk and is along with VAV protein necessary for 
full activation of PLCγ (Pivniouk et al., 1999). In addition to this main Lyn-LAT- PLCγ pathway, 
alternative Fyn-Gab2-PI3K axis was described which is believed to be associated with NTAL 
adaptor protein (Rivera, 2005). Grb2-associated binding protein 2 (Gab2) is phosphorylated by Src 
kinase Fyn and this leads to activation of PI3K which then phosphorylates phosphatidylinositol 
(4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3). Accumulation of PIP3 
in the plasma membrane provides docking sites for proteins containing pleckstrin-homology (PH) 
domains such as PLCγ, Akt and TEC-family kinase Burton’s tyrosine kinase (Btk). Akt is known to 
stimulate transcription of prosurvival genes and through activation of nuclear factor-κB (NF-κB) 
induces generation of cytokines. Recently, it was discovered that IκB kinase 2 phosphorylates 
SNAP-23 which then facilitates fusion of secretory granules with plasma membrane and thus 
promotes degranulation (Suzuki and Verma, 2008). Btk was shown to phosphorylate and therefore 
activate PLCγ (Hata et al., 1998). It is therefore obvious that both Lyn- and Fyn-mediated pathways 
converge to the same effector, although it seems that latter is responsible for maintenance, but not 
the initiation of the signal (Tkaczyk et al., 2004). 
Active PLCγ then cleaves plasma membrane PIP2 into two molecular messengers  diacylglycerol 
(DAG) and inositol (1,4,5) trisphosphate (IP3). While membrane-bound DAG serves as activator of 
PKC, soluble IP3 diffuses to ER membrane and opens calcium channels which leads to release of 
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Ca2+ from ER lumen to cytosol. After depleting ER calcium store, calcium sensor stromal 
interaction molecule 1 (STIM1) triggers calcium influx by opening Orai channels in plasma 
membrane. This prolonged calcium signal is necessary for proper activation of nuclear factor of 
activated T-cells (NFAT) which again turns on various cytokine genes. Moreover, calcium together 
with DAG activates PKC which also regulate transcription but more importantly stimulates 
degranulation (Vig and Kinet, 2009). 
Mast cells also express other receptors on their surface such as Fcγ receptors which can be either 
stimulatory or inhibitory, receptor tyrosine kinase c-kit and several G protein-coupled receptors for 
different ligands. Signal from all of these receptor converge at different points with above-
mentioned cascades and modifies threshold for mast cell activation (Gilfillan et al., 2009; Kuehn et 
al., 2008). 
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Fig. 3 – Overview of mast cell signaling 
When the tetrameric FcεRI receptor (consisting of α,β and γ2 chains) with bound IgE antibody is 
crosslinked with multivalent antigen (Ag), Src-family kinases Fyn and Lyn phosphorylate ITAM 
motifs  and associated Syk kinase. Lyn and Syk then phosphorylate transmembrane adaptor proteins 
LAT and NTAL which harbor Grb2-SOS-Shc complexes that activate Ras-Raf-MEK-Erk cascade. 
Erk can either activate gene transcription or PLA2 activity which leads to eicosanoids production. 
LAT also binds GADS-SLP-76-Vav complex which helps to activate PLCγ. Alternatively Fyn can 
activate PLCγ through Gab2-PI(3)K-PI(3,4,6)P3-Btk pathway. PLCγ then cleaves PI(4,5)P2 into 
DAG and IP3 which releases Ca
2+ from ER by opening IP3R channels. Decrease in calcium content 
in ER is sensed by STIM1 which then opens calcium-release-activated-calcium (CRAC) channels 
consisting of Orai1 subunits in plasma membrane. Elevated calcium level activates NFAT 
transcription factor and together with DAG also PKC, which activate gene transcription and also 
degranulation. Akt kinase stimulate gene transcription alone and also through NFκB pathway. IKK 
also activate SNAP-23 which mediates fusion of granules with plasma membrane (Kalesnikoff and 
Galli, 2008). 
3.3 CD9 and other tetraspanins in the context of mast cells signaling 
Despite extensive study of CD9 and other tetraspanin members, our current knowledge of their 
implication in mast cells remains limited to a few reports. First of all, direct interaction between 
CD9 and FcεRI receptor was confirmed in human CD9-transfected RBL cells. Monoclonal antibody 
against CD9 activated these cells in concentration dependent manner, but addition of IgE 
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suppressed this effect which suggests that activation is mediated by colligation of CD9 with FcεRI 
(Higginbottom et al., 2000b). Another study showed that anti-CD81 antibody inhibited FcεRI-
mediated degranulation in both in vitro and in vivo. Surprisingly, no detectable effect on global 
phospho-tyrosine pattern, calcium release or leukotrien synthesis was observed (Fleming et al., 
1997). Similar results were obtained with anti-CD63 antibody. However, inhibition of degranulation 
was present only in adherent cells and in addition anti-CD63 antibody inhibited also adhesion to 
fibronectin and vitronectin. Using specific inhibitors revealed that these effects were caused by 
impairment of Gab2-PI3K pathway (Kraft et al., 2005). Another indication of possible IP3K 
involvement in CD9 effects is report that CD9 works as an alternative IL-16 receptor in mast cells. 
When CD9 expression level is downregulated by antisense oligonucleotides, IL-16 binding and 
chemotactic response to this cytokine are inhibited. Furthermore, anti-CD9 antibody blocks IL-16-
mediated activation and associated calcium response (Qi et al., 2006). All three tetraspanins CD9, 
CD63 and CD81 were found physically associated with receptor tyrosine kinase c-kit. It was 
proposed that tetraspanins negatively modulate c-kit function and thus its sensitivity to SCF. This is 
because tetraspanin-associated fraction of c-kit has lower kinase activity in basal state and also after 
SCF stimulation (Anzai et al., 2002). 
Eosinophills are minor fraction of blood-circulating granulocytes related to mast cells. It was 
shown that immobilized anti-CD9 antibody activated these cells and this was reversed by anti-β2 
integrin antibody. Antibody against CD9 also stimulated cell survival by autocrine production of 
granulocyte macrophage colony-stimulating factor (GM-CSF) (Kim et al., 1997). 
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4 Materials and methods 
4.1 Cell cultures 
4.1.1 BMMCs 
Bone marrow cells were isolated from femurs and tibias of 6–10 weeks old mice. The cells were 
then kept in suspension culture for 4–8 weeks in complete medium IMDM supplemented with 10% 
fetal calf serum (FCS), 41µM 2-mercaptoethanol, 100 U/ml penicillin, 100 µg/ml streptomycin, 
murine recombinant IL-3 (36 ng/ml; PeproTech EC) and murine recombinant SCF (36 ng/ml; 
PeproTech EC) at 37°C in an atmosphere of 10% CO2. Before conducting the experiments, the cells 
were assayed for high level of FcεRI expression using flow cytometry analysis and tested for their 
ability to degranulate in response to antigen – TNP conjugated to BSA (TNP-BSA) using β-
glucuronidase assay. 
4.1.2 Immortalized BMMCs 
Immortalized BMMCs were kindly provided by M. Hibbs (Ludwig Institute for Cancer 
Research, Melbourne, Australia). Suspension cultures were grown in IMDM medium supplemented 
with 10% FCS, 41µM 2-mercaptoethanol, 100 U/ml penicillin, 100 µg/ml streptomycin and 10% 
WEHI supernatant as a source of IL-3 at 37°C in a humidified atmosphere of 10% CO2. 
Immortalized BMMCs were used for experiments from chapter 5.7 to chapter 5.12. 
4.1.3 Rat basophilic leukemia cell line 
Subclone 2H3 of RBL cell line (RBL-2H3) originally acquired from H. Metzger (NIH, 
Bethesda, MD) was maintained in RPMI-1640 medium supplemented with 100 U/ml penicillin, 100 
µg/ml streptomycin and 10% FCS. Monolayer cultures were passaged every 2–3 days and kept in 
humidified and 5% CO2 atmosphere at 37°C. 
4.1.4 293 T/17 cell line 
Human embryonic kidney 293 T/17 cells were purchased from American Type Culture 
Collection (ATCC) (Manassas, VA, USA). The cells were grown as an adherent monolayer culture 
in DMEM medium containing 10% FCS, 100 U/ml penicillin and 100 µg/ml streptomycin. Cultures 
were passaged regularly every 4–5 days and kept at 37°C at an atmosphere of 5% CO2. 
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4.2 β-glucuronidase assay 
BMMCs were incubated at concentration 6.66 × 106/ml in cytokine-free medium (IMDM 
containing 10% FCS, 41 µM 2-mercaptoethanol, 100 U/ml penicillin and 100 µg/ml streptomycin) 
with 1000× diluted 2,4,6-trinitrophenyl  (TNP)-specific IgE ascites (IGEL) for 4 hours or overnight 
at 37°C. Subsequently, cells were 3× centrifuged at 290 × g for 5min at room temperature and 
washed with balanced salt saline containing 0.1% bovine serum albumin (BSS-BSA). They were 
then transferred into 30 µl U-bottom 96-well plate (P-lab, Prague, Czech Republic) at a 
concentration 7 × 106/ml, mixed with 30 µl of TNP-BSA (1 µg/ml) and incubated at 37°C for 
indicated time. As positive control 30 µl of 0.1% Triton X-100 instead of TNP-BSA was added. 
Activation was stopped by placing plate on ice and adding 60 µl of cold BSS-BSA. After 
centrifugation (290 × g, 5min, 4°C) 30 µl of supernatant was transferred to flat-bottom white 
FluoroNunc plate (Nunc, Roskilde, DK) and 30 µl of 60 µM 4-Methylumbelliferyl β-D-
Glucuronide (MUGlcU) substrate in acetate buffer (pH 4.4) was added and incubated at 37°C for 30 
min. Reaction was terminated by addition of 200 µl cold glycine buffer (pH 10), and amount of 
fluorescent product was assessed by reading the plate with Infinite 200M (Tecan Group Ltd., 
Männedorf, CH) plate reader instrument at excitation and emission wavelength, 355 nm and 460 nm 
respectively. Alternatively, in some experiments thapsigargin instead of TNP-BSA was added. 
4.3 Calcium assay 
BMMCs were washed 2× with BSS-BSA and resuspended in BSS-BSA supplemented with 
2.5mM probenecid and 1 µg/ml Fura-2 AM at a concentration 6 × 106/ml. After 30 min incubation 
in water bath at 37°C, the cells were washed and resuspended in BSS-BSA containing probenecid 
and incubated for another 15 min at 37°C to fully hydrolyze Fura-2 dye. Subsequently, the cells 
were washed with BSS-BSA supplemented with probenecid ,  resuspended at a concentration 4 × 
106/ml in BSS-BSA and 50 µl of this suspension was transferred to flat-bottom white FluoroNunc 
plate (Nunc, Roskilde, DK) and measured on Infinite 200M plate reader (Tecan Group Ltd., 
Männedorf, CH). Calcium response was triggered by injection of an equal amount of 2× 
concentrated activator. Alternatively, same amount of 3× concentrated second activator was 
injected at specified times after first injection. Fluorescence was recorded from dual excitation (340 
nm, 380 nm) and single emission 510 nm wavelength. Final Ca2+ curve was calculated as ratio of 
emission with excitation at 340 nm and 380 nm in same cycle. 
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4.4 Preparation of tissue lysates and protein quantification assay 
Mouse was sacrificed and extracted organs were kept on ice. Approximately equal-weight piece 
of each organ (where applicable) was transferred to 1 ml of ice-cold organ-lysis-solution. All 
samples were homogenized for 5 min by electric homogenizer and incubated on ice for 30 min. In 
order to break down DNA aggregates, samples were repeatedly aspirated through medical needle (Ø 
1.20 × 40 mm) and then centrifuged (14,000 × g, 10 min, 4°C). Protein content in samples was then 
quantified using DC Protein Assay (Bio-Rad Laboratories, Hercules, CA) according to 
manufacturer’s protocol. Absorbance of samples was read at 750 nm on Infinite 200M plate reader 
and protein concentrations were calculated from bovine serum albumin (BSA) standard curves. All 
samples were then diluted with organ-lysis-solution to obtain final protein concentration 1.66 
mg/ml. Subsequently, 30 µl was mixed with 2× concentrated sample buffer and resolved on sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
4.5 Immunoprecipitation and covalent coupling of antibody to 
protein G 
All steps were performed on ice or at temperature 4°C unless otherwise stated. Protein G 
Ultralink resin (Pierce, Rockford, IL, USA) was incubated with antibody diluted in phosphate 
buffered saline (PBS) for 1.5 h with continual agitation. Resin was then washed 2× with PBS and 
2× with 10 volumes of borate buffer. Finally, resin was resuspended in 10 volumes of borate buffer 
supplemented with dimethyl pimelimidate (DMP) (20mM) and incubated for 30 min at room 
temperature with constant agitation. Reaction was quenched by 2× washing and then incubating the 
resin with Tris-HCl (1M, pH 8.0) for 2 h at room temperature. Non-cross-linked proteins were 
eluted by washing 2× with glycine buffer (pH 2.5) and then neutralized with lysis buffer. 
BMMCs were lysed in lysis buffer A supplemented with 1% Triton X-100 for 30 min. Lysate 
was centrifuged (14,000 × g, 10 min, 4°C) and cleared supernatant was added to Protein G Ultralink 
resin (6.6×106 cells/10 µl of resin). After 2 h incubation with continual agitation, the resin was 3× 
washed with lysis buffer A supplemented with 1% Triton X-100 and 1× with lysis buffer A alone to 
remove unbound proteins. Antigen was eluted by boiling with 1× concentrated sample buffer (non-
reducing) for 5 min and then separated on SDS-PAGE. 
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4.6 Protein analysis 
4.6.1 SDS-PAGE 
Cells were lysed in cold lysis buffer B containing 1% NP-40 and 1% Lauryl maltoside for 30 
min and then centrifuged (10 min, 14,000 × g, 4°C). Supernatant was diluted with 2× concentrated 
sample buffer (reducing or non-reducing). In case of immunoprecipitation with antibody bound to 
protein G immobilized on agarose beads, 1× concentrated sample buffer was used for antigen 
elution. Before loading, the samples were boiled for 5 min and then resolved by 10% or 15% 
separating gel with 4% stacking gel. Electrophoretic separation was performed using Mini-protean 
II (Bio-Rad Laboratories, Hercules, CA) with constant voltage setting 100 V for 15 min and then 
120 V for 75 min. 
4.6.2 Western blotting and protein immunodetection on nitrocellulose membrane 
Gel was rinsed in transfer buffer and then used for transferring size-fractioned proteins onto 
nitrocellulose membrane (Schleicher a Schuell BioScience, Inc., Keene, NH) with dimensions 8.5 
cm × 6 cm. Western blotting was performed using Mini Trans-Blot (Bio-Rad Laboratories, 
Hercules, CA) system at constant current 200 mA for 90 min. 
Nitrocellulose membrane was first washed for 15 min in Tris-NaCl-Tween (TNT) buffer and 
then blocked by incubation in TNT supplemented with 2% BSA for 1 h. Subsequently, the 
membrane was probed with primary antibody diluted in TNT containing 2% BSA for 1 h, followed 
by 3× 5 min wash with TNT. Membrane was then incubated with secondary antibody conjugated 
with horseradish peroxidase (HRP), diluted in TNT supplemented with 0.5% nonfat dry milk for 1 
h. In case of anti-phosphotyrosine primary antibody (PY-20) conjugated with HRP, probing was 
performed in TNT supplemented with 0.5% nonfat dry milk. Membrane was then washed as 
previous, incubated in enhanced chemiluminiscence (ECL) for 1 min, placed on plastic pad and 
covered with Saran foil (Dow Chemical Company). Luminescent signal was detected by LAS-3000 
imaging instrument (Fuji Photo Film Co.). 
4.6.3 Protein staining in the gel by Coomassie Brilliant Blue R-250 
Polyacrylamide gel was fixed and stained overnight in staining solution. After that, the gel was 
destained by rinsing with destining solution. For long-term storage, the gel was kept in 1% acetic 
acid. 
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4.6.4 Sample preparation for mass spectrometry (MS) analysis 
Spot of our interest was excised from the gel, cut into small pieces and washed several times 
with 0.1M 4-ethylmorpholine acetate (pH 8.1) in 50% acetonitrile. After complete destaining, 50 
mM tris(2-carboxyethyl)phosphine (TCEP) was added to the gel pieces and incubated for 15 min at 
80°C. Then the gel pieces were washed in water and 100mM iodoacetamide (IAA) solution was 
added for 40 min in the dark. The gel was washed with deionized water, shrunk by dehydration in 
acetonitrile. The supernatant was removed, and the gel was partly dried in SpeedVac concentrator. 
Gel pieces were then reconstituted in cleavage buffer containing 50 mM 4-ethylmorpholine acetate, 
10% acetonitrile and sequencing grade trypsin (50 ng/ml, Promega; Madison, WI). 
After overnight digestion at 37°C, the resulting tryptic peptides were extracted with acetonitrile 
in final concentration of 10% and 1% acetic acid. Five microliters of the peptide mixture were 
applied on a reverse phase column (Magic C18, 0.2 × 150 mm, 200Å, 5 µm; Michrom 
Bioresources) and separated using a gradient elution (0–12% B for 10 min and 12–45% B for 90min 
at a flow rate of 2 µl/min). Solvent A was 5% acetonitrile, 0.5% acetic acid and solvent B 95% 
acetonitrile, 0.4% acetic acid. The column was interfaced with an ion trap mass spectrometer 
(LCQDECA ThermoFinnigen) equipped with nanoelectrospray ion source. 
4.7 Generation of CD9 knockdown and overexpressing BMMCs 
4.7.1 Competent cells 
For propagation of plasmid DNA, competent DH5α E. coli cells were used. The cells were 
inoculated into 6 ml of Luria-Bertani (LB) medium and cultivated overnight in orbital shaker 
(Sanyo; 150rpm, 37°C). Next day 1 l of LB medium was inoculated with prepared bacterial culture 
and cultivated under the same conditions till optical density at 600 nm reached interval 0.5–0.7. 
Bacterial cells were then centrifuged (4 000 × g, 4°C, 10 min), supernatant was discarded and pellet 
was resuspended in 500ml of cold 10% glycerol. The cells were washed two more times in 250 ml 
and 125 ml of 10% glycerol respectively. Finally, they were resuspended in 3 ml of cold 10% 
glycerol and stored at −70°C in aliquots. 
4.7.2 Vector construction 
Plasmid pYX-Asc containing full-length CD9 complementary DNA (cDNA) (Open Biosystems, 
Huntsville, AL) and lentiviral expression plasmid pCDH-CMV-MCS-EF1-Puro (System 
Biosciences, Mountain View, CA) were propagated in bacteria and isolated using Lego kit (Top-
Bio s.r.o., Praha, CZ) according to manufacturer protocol. Both vectors were cut by EcoRI 
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(Fermentas, Burlington, Ontario, CA) and NotI (Fermentas) restriction enzymes, separated on 
agarose gel and bands corresponding to cDNA (1314 bp) and linearized pCDH-CMV-MCS-EF1-
Puro (7355 bp) were isolated using TaKaRa RECOCHIP (TAKARA BIO INC., Shiga, Japan) 
according to manufacturers protocol. DNA was precipitated overnight (200 µl of DNA, 50 µl of 3M 
sodium acetate pH 5.2, 1ml of 96% ethanol) at −20°C, washed 3× with 75% ethanol, dryed and 
dissolved in deionized water at 65°C. Purified cDNA fragment was then ligated with linearized 
expression plasmid using T4 DNA ligase (Fermentas)and thus creating plasmid construct termed 
pCDH/CD9. 
4.7.3 Bacterial transformation 
Transformation of E. coli bacterial strain DH5α was carried out by electroporation when 1 µl of 
ligation product was mixed with 40 µl of competent cells and transferred to cold electroporation 
cuvette. The cells were then subjected to electrical pulse of 1.8 kV in Pulser Transformation 
Apparatus (BioRad Laboratories) and immediately supplemented with 1 ml of super optimal broth 
with catabolite repression (SOC) medium. After 60 min incubation on shaker at 37°C, cells were 
seeded on LB agar plate with ampicillin (100 µg/ml) and grown bottom up at 37°C overnight. 
Six colonies were used for inoculation of 3 ml of LB media containing ampicillin (100 µg/ml). 
Plasmid was isolated using Lego kit, all clones were verified by restriction digest by PvuII (New 
England Biolabs, Ipswich, MA; generates 4 fragments, one with increased molecular weight in case 
of successful insertion) and ApaI (New England Biolabs; cleaves only inside cDNA sequence) and 
one clone was then verified by sequencing from cytomegalovirus (CMV) promoter. 
4.7.4 Generation of lentiviral particles and cells infection  
To generate lentiviral particles for stable and effective BMMCs transformation, production cell 
line 293 T/17 cells were transfected with desired lentiviral vector and vectors essential for viral 
particles production.  At first, 82µl of Lipofectamine was mixed with 1 ml of OPTI-MEM medium 
and incubated for 5 min at room temperature. Then 500 µl of OPTI-MEM containing 21 µl (1 
µg/ml) of packaging vectors equimolar mixture (pPL1, pPL2, VSVG) and 14 µg of desired 
lentiviral vector (maxiprep isolated) was added. After gentle agitation, the mixture was left to react 
at room temperature for 20 min. 293 T/17 cells were grown in 150 cm2 plastic culture bottles to 
subconfluency and old medium was removed and changed for 10 ml of fresh DMEM medium 
without antibiotics. The tranfection mixture was then mixed with 10 ml of DMEM medium without 
antibiotics and added to the cells. After brief swirling, the culture bottles were placed into incubator 
(37°C, 10% CO2) and incubated for at least 6 h. The medium used for transfection was then 
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replaced with 25 ml of new DMEM medium with antibiotics. The cells were then cultivated for 
another 3 days. Supernatant was then subjected to brief centrifugation (290 × g, 10 min) to remove 
dead cells and debris and then centrifuged at higher speed (75,600 × g, 2h, 4°C) to collect viral 
particles. Supernatant was then discarded and pelleted viral particles were resuspended to 1 ml of 
complete media by repetitive aspiration with insulin needle. Viral suspension was then added to 
required amount of BMMCs (1 × 106/ml) in complete medium without antibiotics and cells were 
incubated for 2 days. Medium was then replaced with complete medium supplemented with 
puromycin (5 µg/ml) and infected cells were selected for 4 days. The cells were regularly passaged 
and kept in complete medium containing puromycin (2 µg/ml). 
4.7.5 Plasmid miniprep 
Minipreparative plasmid isolation from bacteria was performed using commercial DNA Lego kit 
according to manufacturer’s protocol. Briefly, 3 ml of LB medium supplemented with ampicillin 
(100 µg/ml) was inoculated with bacteria carrying plasmid of interest and incubated in orbital 
shaker overnight at 37°C. Then 1.5 ml of bacterial suspension was centrifuged (14,000 × g, 30 s) 
and pellet was resuspended in 200 µl of suspension solution. The cells were lysed by addition of 
200 µl of Lysis solution, mixed by inversion and incubated for 5 min. Lysis was terminated by 200 
µl of neutralization solution, mixed by slow inversion and centrifuged (14,000 × g, 7 min).  
Meanwhile minicolumns were attached to Vac-Man Laboratory vacuum manifold (Promega, 
Madison, WI) and 100 µl of DNA bind particle suspension was loaded. Cleared supernatant was 
then mixed with 600 µl of DNA binding buffer and loaded onto column with DNA bind particles. 
Solution was then sucked through the column by applying vacuum and washed by 2 ml of Wash 
buffer. DNA was eluted by centrifugation (14,000 × g, 1min) with deionized water preheated to 
50°C. DNA purity and concentration was measured using Nanodrop instrument (Thermo Scientific, 
Wilmington, DE). 
4.7.6 Plasmid maxiprep 
Bacterial cells were inoculated into 3 ml of LB medium supplemented with ampicillin (100 
µg/ml) and cultivated in orbital shaker at 37°C overnight. Bacterial suspension was then used to 
inoculate 1 l of LB medium with ampicillin (100 µg/ml) and cultivated as previously. Next day, the 
bacterial suspension was cooled on ice and centrifuged (4,620 × g, 12min, 4°C). Pelleted cells were 
resuspended in 64 ml of GTE solution and lysed for 10 min on ice by adding 128 ml of NaOH/SDS 
solution and mixed by slow inversion. Lysis was stopped with 64 ml of KAc/Ac solution and 
intensive shaking.  Lysate was centrifuged (4000 × g, 20 min, 4°C), supernatant was filtered 
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through sterile gauze and precipitated in 74 ml of ice-cold isopropanol for 30 min on ice. After 
centrifugation (4000 × g, 20 min, 4°C), supernatant was discarded, pelleted DNA was dried and 
then dissolved in 8 ml of Tris-EDTA (TE) buffer for 10 min at 65°C. Into fully dissolved DNA 
solution, 9.2 g of CsCl and 0.25ml of ethidium bromide (EtBr) (10 mg/ml) was added. The solution 
was then transferred into two 5 ml centrifugal tubes (Beckman Instruments,Inc., Palo Alto, CA) and 
ultracentrifuged (65,000 rpm, 16 h, 18°C, NVT 90 rotor, Ultracentrifuge L-70, Beckman 
Instruments,Inc., Palo Alto, CA) till equilibrium. Tubes were carefully pierced with needle and 
approximately 1–2 ml of solution (containing lower EtBr band consisting of plasmid) was aspirated. 
Recovered solution was then mixed with 100 µl of EtBr (10 mg/ml), 9 g of CsCl and 8 ml of TE 
buffer and loaded into new centrifugal tubes. Plasmid was again separated on CsCl gradient by 
ultracentrifugation (70,000 rpm, 6 h, 18°C, NVT 90 rotor, Ultracentifuge L-70) and extracted as 
before. To remove remaining EtBr from plasmid sample, the solution was 5× mixed with 8 ml of 
butanol, briefly centrifuged and upper butanol phase was discarded. For each ml of cleared plasmid 
solution, 1ml of TE buffer, 100 µl of 3M sodium acetate and 2 ml of 96% ethanol cooled to −20°C 
were added and mixture was precipitated for at least 2 h at −20°C. The precipitate was then 
centrifuged (27,216 × g, 20 min), pellet was mixed with 10 ml of 70% ethanol by wortexing and 
centrifuged again (20min, 7,000 rpm). Purified and pelleted plasmid was then dried in vacuum and 
dissolved in 1 ml of TE buffer. Small aliquots were stored at −70°C. 
4.8 Labeling of TNP-BSA with tetramethyl rhodamine isothiocyanate 
(TRITC) 
TNP-BSA (2.5 mg/ml) was first dialyzed overnight against carbonate/bicarbonate buffer 
(100mM, pH 9.6). Then, 35 µl of TRITC (1mg/ml) dissolved in non-aqueous dimethyl sulfoxide 
(DMSO) was slowly added to 0.5 ml of dialyzed TNP-BSA while stirring. Mixture was incubated 
for 2 h at room temperature in the dark. Excess of TRITC was removed by overnight dialysis 
against PBS. TNP-BSA-TRITC was immediately used for experiments or stored at −20°C in 
aliquots. 
4.9 Flow cytometry 
Flow cytometry was used for detection of surface antigens on BMMCs. Non-sensitized cells 
were probed by incubation for 30 min at 4°C with primary antibody diluted in 20% complete 
medium in PBS (CM/PBS). In case of Fc receptor was being detected, the cells were sensitized with 
IgE as described previously. Cells were then washed 2× with CM/PBS followed by incubation with 
anti-rat IgG secondary antibody conjugated to fluorescein isothiocyanate (anti-rat-IgG-FITC) 
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diluted in CM/PBS (1:300) for 30min at 4°C. After 2× wash with CM/PBS, the cells were 
resuspended in cold PBS and analyzed on FACSCalibur or LSR II flow cytometer (BD Biosciences, 
San Jose, CA, USA) in FL1 channel. 
When level of antigen binding to IgE-loaded Fc receptor was being assessed, cells were 
sensitized as usual and then incubated with TNP-BSA-TRITC (1 µg/ml) in BSS/BSA for 30 min at 
37°C. Excess of unbound TNP-BSA-TRITC was removed by 2× wash with cold BSS/BSA and 
cells were then resuspended in cold PBS. Fluorescence of bound antigen was measured on flow 
cytometer in FL2 channel. 
4.10 Phosphatidylinositol-specific phospholipase C (PI-PLC) assay 
Cells were washed 2 × in BSS-BSA, centrifuged and supernatant was removed. Pellet was 
resuspended in complete medium supplemented with PBS and PI-PLC (1 × 106 cells per 50 µl of 
medium containing 2 µl of PI-PLC) and incubated 40 min at 37°C. Cells were then washed 2×, 
labeled with appropriate antibodies and decrease in surface content of examined proteins were 
analyzed by flow cytometry. 
4.11 Preparation of rat monoclonal antibodies against BMMCs 
membrane antigens 
Murine BMMCs were permeabilized in PBS supplemented with Saponin (final concentration 
0.1%) and MgCl2 (10mM), centrifuged and sedimented membrane fraction was used for 
immunization of rat (strain Wistar). Interspecies hybridomas were created by fusion of rat spleen 
cells with murine myeloma cell line (SP2/0). Hybridomas were then cloned and supernatants from 
individual clones were subjected to testing for the presence of antibodies capable of binding to 
surface antigens of BMMCs as detected by flow cytometry analysis. Clones with the best binding 
ability were picked and also tested for their reactivity to BMMCs lysate on western blot. 
4.12 Purification of 2H9 antibody and normal rat serum IgG 
For 2H9 antibody purification, hybridoma cells (prepared as described in 4.11) were cultivated 
in RPMI-1640 medium supplemented with 10% FCS until color of the medium became pale 
yellow. Cells were then centrifuged and supernatant was either immediately used for purification of 
IgG antibodies or stored for further use at −20°C. 
In case of IgG antibodies isolation from normal serum, non-immunized rat was sacrificed and 
collected blood was clotted at room temperature. Clot was then centrifuged at 290 × g for 5 min. 
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Serum supernatant was collected, diluted 1:1 with PBS containing 0.5 M NaCl and immediately 
used for purification. 
Purification of IgG faction of antibodies was performed by immunoaffine chromatography using 
anti-rat IgG-Agarose (Sigma-Aldrich, St. Louis, MO). Column was first equilibrated by wash with 
PBS supplemented with 0.5 M NaCl and then either hybridoma supernatant or rat serum was slowly 
applied. Column was then again washed with PBS containing 0.5 M NaCl and bound antibodies 
were eluted with elution buffer. Each fraction was neutralized by addition of 1 M Tris pH 8.0. 
Fractions were assayed for protein content on NanoDrop ND-1000 spectrophotometer (NanoDrop 
products, Wilmington, DE, USA) using Protein A280 program. Those with highest concentration 
were combined and dialyzed against PBS overnight using 25,000 molecular weight cut off dialyzing 
Spectra/Por membrane (Spectrum Laboratories, Inc., Rancho Dominguez, CA, USA). Product was 
then concentrated to desired concentration with NANOSEP 30K OMEGA (Pall Life Sciences, MI, 
USA) with 30,000 molecular weight cut off value. 
4.13 Antibody isotyping 
Isotyping was performed with IsoStrip Isotyping kit (Cat.No. 1 493 027, Roche Diagnostics, 
Indianapolis, IN, USA) following the manufacturer’s protocol. Antibody of interest was first diluted 
in PBS and bound to blue latex beads coated with antibodies specific for light chain. Isotyping strip 
was then dipped into latex bead solution. After leading edge reached the control position, strip was 
removed and results were read as blue bands on strip in areas with immobilized antibody specific 
for given isotype. 
4.14 Statistical analysis 
Statistical significance was determined using  an unpaired Student’s t test: *, P<0.05. 
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4.15 List of chemicals and material 
2-mercaptoethanol MERCK-Schuchardt, Hohenbrunn, SRN 
Acetic acid Lachema a. s., Neratovice, CZ 
Acrylamide Fluka Chemie GmbH, Buchs, Switzerland 
Agarose Top-Bio s.r.o., Praha 
Ammonium persulfate Sigma-Aldrich, St. Louis, MO 
anti-actin Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA 
anti-CD48 Developed in our laboratory 
anti-CD9 (KMC8.8) Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA 
anti-CD9 (N-19) Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA 
anti-goat-IgG-Cy3 Jackson ImmunoResearch Laboratories, Inc., West Grove, PA,  
USA 
anti-mouse-IgG-FITC Sigma-Aldrich, St. Louis, MO 
anti-mouse-IgG-HRP Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA 
anti-phosphoPLCγ1 Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA 
anti-phosphotyrosine (PY20) BD, Franklin Lakes, NJ, USA 
anti-rabbit-IgG-HRP Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA 
anti-rat-IgG Jackson ImmunoResearch Laboratories, Inc., West Grove, PA,  
USA 
anti-rat-IgG-FITC Sigma-Aldrich, St. Louis, MO 
anti-rat-IgG-HRP A5795, Sigma-Aldrich, St. Louis, MO 
anti-Thy1.1 (OX-7) Developed in our laboratory 
Aprotinin Carl Roth GmbH, Karlsruhe, D 
Calcein AM Molecular Probes, Eugene, Oregon, USA 
Calcium chloride Sigma-Aldrich, St. Louis, MO 
Coomassie Brilliant Blue R-
250 
Serva, Heidelberg, D 
Dimethyl pimelimidate Fluka Chemie GmbH, Buchs, Switzerland 
DMSO Fluka Chemie GmbH, Buchs, Switzerland 
EcoRI Fermentas International Inc., Ontario, Canada 
EDTA Carl Roth GmbH, Karlsruhe, D 
Ethanol Lachema a. s., Neratovice, CZ 
Fura-2 AM Molecular Probes, Eugene, Oregon, USA 
Glucose Sigma-Aldrich, St. Louis, MO 
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Glycerol Sigma-Aldrich, St. Louis, MO 
Glycin Sigma-Aldrich, St. Louis, MO 
HEPES Sigma-Aldrich, St. Louis, MO 
IL-3 PeproTech Inc., Rocky Hill, NJ, USA 
Lauryl maltoside Apollo scientific Ltd., Cheshire, UK 
Lipofectamine Invirtogen, Carlsbad, CA, USA 
Luminol Sigma-Aldrich, St. Louis, MO 
Magnesium chloride Fluka Chemie GmbH, Buchs, Switzerland 
Methanol Lachema a. s., Neratovice, CZ 
MUGlcU Molecular Probes, Eugene, Oregon, USA 
Nonfat dry milk Super G, Inc., Landover, MD, USA 
NP-40 USB, Cleveland, Ohio, USA 
OPTI-MEM Gibco, Carlsbad, CA, USA 
p-coumaric acid Sigma-Aldrich, St. Louis, MO 
Penicilin Biotika a.s., Slovenská Ľupča, SR 
PI-PLC Boehringer Mannheim GmbH, Germany 
PMSF Sigma-Aldrich, St. Louis, MO 
Ponceau S Sigma-Aldrich, St. Louis, MO 
Potassium chloride Carl Roth GmbH, Karlsruhe, D 
Probenecid Sigma-Aldrich, St. Louis, MO 
Puromycin InvivoGen, San Diego, California, USA 
Saponin Sigma-Aldrich, St. Louis, MO 
SCF PeproTech Inc., Rocky Hill, NJ, USA 
SDS Carl Roth GmbH, Karlsruhe, D 
Sodium acetate Lachema a. s., Neratovice, CZ 
Sodium orthovanadate Sigma-Aldrich, St. Louis, MO 
Streptomycin Sigma-Aldrich, St. Louis, MO 
Thapsigargin Sigma-Aldrich, St. Louis, MO 
Tris Sigma-Aldrich, St. Louis, MO 
TRITC Fluka Chemie GmbH, Buchs, Switzerland 
Triton X-100 USB, Cleveland, Ohio, USA 
TWEEN 20 USB, Cleveland, Ohio, USA 
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4.16 Buffers, Solutions and Media 
Acetate buffer 
0.1 M Sodium acetate 
0.5 M NaOH 
pH 4.4  with HCl 
Glycine buffer 
0.35 M Glycine 
0.44 M Na2CO3 
pH 10.0 with NaOH 
BSS-BSA 
0.1 % BSA 
135 mM NaCl 
5 mM KCl 
1.8 mM CaCl2.H2O 
5.6 mM Glucose 
20 mM HEPES 
pH 7.4  
PBS 
137 mM NaCl 
2.7 mM KCl 
8 mM Na2HPO4 
2 mM KH2PO4 
pH 7.4  
LB medium 
1% Bacto-tryptone 
0.5% Bacto-yeast extract 
86 mM NaCl 
pH 7.0 with NaOH 
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LB agar 
1% Bacto-tryptone 
0.5% Bacto-yeast extract 
86 mM NaCl 
1.6% Bacto agar 
pH 7.0 with NaOH 
SOC medium 
2% Bacto-tryptone 
0.5% Bacto-yeast extract 
10 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
20 mM Glucose 
GTE solution 
50 mM Glucose 
25 mM Tris 
10 mM EDTA 
NaOH/SDS solution 
0.2 M NaOH 
1% SDS 
KAc/Ac solution 
3 M Potassium Acetate 
11.5% Acetic acid 
TE buffer 
10 mM Tris 
1 mM EDTA 
pH 8.0  
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Sample buffer 
125 mM Tris 
20% Glycerol 
(10% 2-mercaptoethanol) 
4% SDS 
5% Bromophenol blue 
pH 6.75 with HCl 
Lysis buffer A 
20 mM Tris 
100 mM NaCl 
2 mM EDTA 
0.02 µg/ml Aprotinin 
0.1 mg/ml PMSF 
pH 8.0  
Lysis buffer B 
20 mM Tris 
135 mM NaCl 
2 mM EDTA 
(1mM Na3VO4) 
0.02 µg/ml Aprotinin 
0.1 mg/ml PMSF 
pH 7.5  
Transfer buffer 
27 mM Tris 
0.2 M Glycine 
10% Methanol 
pH 8.3  
TNT 
10 mM Tris 
0.1 M NaCl 
0.1% Tween-20 
pH 7.5  
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ECL 
100 mM Tris 
1.25 mM Luminol 
0.2 mM p-coumaric acid 
0.006% H2O2 
pH 8.8  
Carbonate/bicarbonate buffer 
32 mM Na2CO3 
68 mM NaHCO3 
pH 9.6  
Borate buffer 
0.2 mM Na2B4O7·10H2O 
pH 9.0 with H3BO3 
Glycine buffer (pH 2.5) 
0.1 mM Glycine 
pH 2.5 with HCl 
Elution Buffer 
0.1 mM Glycine 
150 mM NaCl 
pH 2.4 with HCl 
Staining solution 
0.05% Coomassie Brilliant Blue R-250 
45% Methanol 
10% Acetic acid 
Destaining solution 
25% Methanol 
10% Acetic acid 
Ponceau S staining solution 
0.1% Ponceau S 
5% Acetic acid 
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5 Results 
5.1 Generation of rat monoclonal antibodies against BMMCs 
membrane antigens 
Monoclonal antibodies proved themselves in past as a useful and unique tool in biological 
research and particularly in case where they enabled identification of new important signaling 
molecules or unravel their unknown function (Williams et al., 1977). In our laboratory we have 
prepared and extensively used several monoclonal antibodies specific for membrane antigens of rat 
RBL cells (Hálová et al., 2002; Smrž et al., 2007; Smrž et al., 2008). Because monoclonal 
antibodies against membrane antigens of murine BMMCs were limited, we decided to generate new 
antibodies against such antigens with the aim to use them as unique tools which could potentially 
harbor yet unidentified role of membrane structure in mast cell activation and degranulation 
processes. 
My contribution in this part of work was limited to selection of antibodies and thus I refer to 
Materials and methods section (4.11) for description of monoclonal antibodies preparation. From 
the palette of preselected antibodies one clone with full name 1/2H9/3D3/1A1 (later on termed as 
2H9) was chosen as a potential candidate for target protein identification.  
At first, binding ability of the antibody to its cell-surface target was necessary to be verified. For 
this purpose alive BMMCs were incubated with 30 µg/ml of 2H9 antibody isolated from cell culture 
media (see below) or 1000× diluted serum from BMMCs-immunized rat as a positive control. After 
washing the cells were probed with anti-rat-IgG-FITC secondary antibody and then analyzed by 
flow cytometry. Shift in fluorescence intensity in FL1 channel compared to cells probed with 
secondary antibody alone indicated that 2H9 antibody efficiently binds to its membrane target (Fig. 
4).  
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Fig. 4 – Binding of 2H9 antibody to its target protein on the surface of BMMCs analyzed by 
flow cytometry. 
Binding efficiency of 2H9 antibody was analyzed by flow cytometry in FL1 channel. Red line 
represents background fluorescence of BMMCs treated only by secondary anti-rat-IgG-FITC. Blue 
line represents BMMCs first probed with serum from BMMC-immunized rat (A) or 2H9 antibody 
(B) and then stained with anti-rat-IgG-FITC secondary antibody. 
Antibody was then tested for its ability to detect specific antigen on western blot. BMMCs were 
lysed in lysis buffer B supplemented with 1% Triton X-100 and the lysate was diluted with sample 
buffer (reducing or non-reducing). Amount of lysate corresponding to 6 × 105 cells per line was 
resolved on 12% gel by SDS-PAGE. After western blotting, membrane was probed with 1 µg/ml of 
2H9 antibody and 8000× diluted anti-rat-IgG-HRP. Results in Fig. 5 show that 2H9 antibody 
detects single protein band of approximate molecular weight 24–25 kDa. Furthermore, detection 
with 2H9 antibody is less sensitive under reducing conditions, where it detects faster migrating 
band, compared to non-reducing conditions. This suggests that the antibody binds to a 
conformational epitope stabilized by one or more disulphide bonds. Based on this finding, only non-
reducing sample buffer was used for SDS-PAGE in later experiments. 
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Fig. 5 – Detection of 2H9-target protein in lysate from BMMCs using SDS-PAGE and 
immunoblotting. 
Lysates from BMMCs were diluted with sample buffer either containing(+) or not (-) 2-
mercaptoethanol (ME), resolved on 12% SDS-PAGE gel and blotted onto nitrocellulose membrane. 
Target protein of 2H9 antibody was detected by probing the membrane with 2H9 antibody and anti-
rat-IgG-HRP secondary antibody. Arrow indicates band corresponding to detected protein and 
numbers on the left represent position of molecular weight markers in kDa.  
5.2 Tissue distribution of antibody binding partner 
Information about expression profile in different tissues might be in some cases helpful in 
determination of antigen identity. For this purpose we prepared lysates from various organs of 
BALB/c strain mouse by their homogenization in organ lysis solution. Lysates from BMMCs and 
RBL cells were also included. According to the results from previous experiments, proteins were 
separated on 12% SDS-PAGE gels under non-reducing conditions and target protein was again 
detected as described above. Results of this experiment show that target protein is broadly 
expressed in various types of tissues. Inability to detect 24–25 kDa band in lysate from RBL cells 
implies that antibody probably recognizes epitope, which is mouse specific or target protein 
expression is not present in this cell line (Fig. 6). 
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Fig. 6 – Distribution of 2H9 antibody-target protein among different tissues. 
After lysing organs and cells in organ lysis solution, protein content was determined by DC protein 
assay and lysates containing 50 µg of proteins/line were resolved on 12% SDS-PAGE gel and 
transferred onto membrane by western blotting. Target protein was detected by 2H9 antibody and 
anti-rat-IgG-HRP secondary antibody. Comparable amount of proteins was verified by Ponceau S 
staining (not shown). 
5.3 PI-PLC assay 
Mode of anchor to the plasma membrane is another useful aspect of protein identity. Membrane 
proteins can exist either as integral transmembrane proteins or can be tethered to plasma membrane 
bilayer through glycosyl-phosphatidylinositol (GPI) anchor. To determine whether protein 
recognized by 2H9 antibody is transmembrane or GPI-anchored, phosphatidylinositol-specific 
phospholipase C (PI-PLC), which cleaves phosphoester bond between DAG and PI group, was used 
to cut off all proteins linked to GPI anchor. 
BMMCs were incubated with PI-PLC at 37°C and then probed with 2H9 antibody and anti-rat-
IgG-FITC. As a control, RBL cells were incubated under the same conditions and labeled with anti-
Thy1.1 (OX7) and anti-mouse-IgG-FITC antibodies; Thy-1.1 was selected because it is known GPI-
anchored protein expressed in RBL cells (Dráberová and Dráber, 1993). Cells were then analyzed 
by flow cytometer in FL1 channel. 
Fig. 7 clearly demonstrates that in contrast to control RBL cells, BMMCs did not show decrease 
in overall fluorescence after PI-PLC treatment which suggests that target protein has 
a transmembrane domain. 
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 Fig. 7 – Determination of anchor mode of 2H9 antibody-target protein. 
Content of GPI-anchored Thy1.1 (OX-7) protein in RBL cells (A) and 2H9 target protein in 
BMMCs (B) in plasma membrane after PI-PLC treatment was determined by fluorescent labeling 
and analysis by flow cytometry. Red line represents background fluorescence of cells with FITC-
conjugated secondary antibody only. Blue line represents fluorescence of PI-PLC-non-treated and 
green line fluorescence of PI-PLC-treated cells probed by appropriate primary (OX-7, 2H9) and 
secondary FITC-conjugated antibody. 
5.4 Isotype determination 
Isotype of 2H9 antibody was determined with IsoStrip kit (Roche Diagnostics, IN, USA) 
according to manufacturer protocol. Hybridoma supernatant containing the antibody was 20× 
diluted in PBS and then mixed with latex beads. Isotyping strip was dipped into suspension and 
results were read after 10 min incubation from position of blue bands on strip. As documented in 
Fig. 8, 2H9 antibody is IgG1 subtype with κ (kappa) light chain. 
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Fig. 8 – Identification of 2H9 antibody isotype. 
After blue latex beads reached control area (+), strip was evaluated for 2H9 antibody isotype from 
position of blue bands (indicated by arrows) on strip. 
5.5 Immunoprecipitation and MS analysis 
Mass spectrometry provides good possibility to identify unknown protein, especially in 
combination with searches in peptide mass databases. However, major complication is requirement 
of relatively pure and concentrated protein sample. For this purpose we decided to immunoaffine 
purify target protein from BMMCs lysate with 2H9 antibody bound to protein G resin. To eliminate 
contamination of 24–25 kDa protein with similar mass immunoglobulin light-chain, antibody was 
covalently crosslinked to protein G using DMP. As a control for light-chain contamination, protein 
G resin was incubated with same amount of 2H9 antibody but not with BMMC lysate. Eluted 
sample was resolved on 12% SDS-PAGE and gel was stained with Coomassie Brilliant Blue R-250. 
Band corresponding to previously determined molecular weight was excised (Fig. 9, arrow) and 
analyzed with microcapillary liquid chromatography in combination with electrospray ionization 
tandem mass spectrometry (microHPLC-ESI-MS/MS) and matrix-assisted laser 
desorption/ionization Fourier transform mass spectrometry (MALDI/FTMS) by P. Pompach from 
the Institute of Microbiology AS CR. List of identified peptides are shown in Tab. 1 and Fig. 10. 
Results reveal that unknown antigen is murine CD9 protein. 
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Fig. 9 – Isolated target protein from BMMCs lysate for MS analysis. 
Two samples of protein G resin with covalently bound 2H9 antibody were either incubated or not 
with BMMCs lysate. After elution by heating the resin with sample buffer, samples were resolved on 
12% SDS-PAGE gel and then stained with Coomassie Brilliant Blue R-250. Protein band indicated 
with arrow was excised and analyzed by mass spectrometry. 
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Identified peptides MH+ 
microHPLC-ESI-MS/MS 
K.QLLESFQVK.P 1092.2 
K.ELQEFYKDTYQK.L 1592.7 
K.QLLESFQVKPC(+57)PEAISEVFNNK.F 2578.8 
MALDI/FTMS 
ELQEFYK 956.4762 
QLLESFQVK 1091.6137 
ELQEFYKDTYQK 1591.7736 
Tab. 1 – List of successfully identified peptides by microHPLC-ESI-MS/MS and 
MALDI/FTMS. 
Table shows sequences identified by MS analysis with mass of their appropriate MH+ ions. Their 
position in whole CD9 protein sequence (NCBI Reference Sequence: NP_031683.1) is marked with 
red letters. 
 
Fig. 10 – Peptide spectrum of target protein from MALDI/FTMS analysis. 
Chart represents spectrum of detected peptides from trypsin digested target protein. Mass of 
identified peptides (MH+) and their corresponding peaks are indicated. 
  1 MPVKGGSKCI KYLLFGFNFI FWLAGIAVLA IGLWLRFDSQ TKSIFEQENN HSSFYTGVYI 
 61 LIGAGALMML VGFLGCCGAV QESQCMLGLF FGFLLVIFAI EIAAAVWGYT HKDEVIKELQ 
121 EFYKDTYQKL RSKDEPQRET LKAIHMALDC CGIAGPLEQF ISDTCPKKQL LESFQVKPCP 
181 EAISEVFNNK FHIIGAVGIG IAVVMIFGMI FSMILCCAIR RSREMV 
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5.6 Cross-immunoprecipitation of CD9 protein 
Previous results showed that 2H9 antibody binds to murine CD9 protein. To verify these results, 
CD9 protein was immunoprecipitated by both 2H9 and KMC8.8 (commercial anti-CD9 monoclonal 
antibody). Samples were electrophoretically separated on 12% SDS-PAGE and after western 
blotting, the CD9 protein was detected by either 2H9 (1000×) or KMC8.8 (1000×) and anti-rat-IgG-
HRP (8000×) secondary antibodies. 
Results in the Fig. 11 show that both antibodies immunoprecipitate single band of the same 
weight which can be detected on western blot by both antibodies. Therefore we conclude that our 
monoclonal antibody 2H9 indeed binds to extracellular part of CD9 protein. 
 
Fig. 11 – Cross-immunoprecipitation of CD9 protein by 2H9 and KMC8.8 antibodies. 
BMMCs were lysed in lysis buffer A supplemented with 1% Triton X-100 and used for 
immunoprecipitation of CD9 by 2H9 and KMC8.8 antibodies bound to protein G resin. Samples 
were separated on 12% SDS-PAGE gel, western blotted onto nitrocellulose membrane and detected 
by either 2H9 or KMC8.8 antibody. 
5.7 Degranulation of anti-CD9 treated BMMCs 
5.7.1 Concentration dependence and time course 
Tetraspanin proteins have been studied for considerably long time. Many experiments, in which 
antibodies against various tetraspanin members were used, showed effects on various aspects of 
cellular physiology and behavior (Higginbottom et al., 2000b; Qi et al., 1996; Tanio et al., 1999). 
We therefore decided to use our new monoclonal anti-CD9 antibody (2H9) for studies on possible 
roles of CD9 protein in mast cell physiology. 
IgE sensitized BMMCs were first incubated in BSS-BSA supplemented with various 
concentrations of anti-CD9 antibody (2H9) for 15 min. Unbound antibody was washed out and the 
cells were activated with antigen (TNP-BSA; 0.5 µg/ml) for the indicated time. In case of time zero 
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of activation, no antigen was added. Activation of the cells was determined by amount of β-
glucuronidase released from intracellular granules using β-glucuronidase assay. 
Data from Fig. 12 show that binding of anti-CD9 antibody to BMMCs surface caused significant 
inhibition of antigen-mediated degranulation at all time points and this inhibition was antibody-
concentration dependent. Moreover, binding of anti-CD9 antibody itself (0 min) triggered BMMCs 
degranulation in the absence of antigen. 
 Fig. 12 – Comparison of BMMCs degranulation pretreated with different 2H9 concentration 
at different time-points after activation. 
BMMCs sensitized with TNP-specific IgE were incubated for 15 min with the indicated 2H9 
concentrations of antibody and then activated for specified time with 0.5 µg/ml of TNP-BSA. Extent 
of degranulation was estimated by amount of β-glucuronidase released to supernatant. Data are 
presented as mean ± SD of one experiment performed in triplicate of three similar experiments. 
Statistical significance of differences between antibody treated (15–16 µg/ml) and non-treated (0 
µg/ml). (*, P<0.05) 
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5.7.2 Influence of other monoclonal antibodies 
Previous experiment showed that our monoclonal anti-CD9 antibody causes inhibition of 
antigen-mediated BMMCs degranulation when bound to CD9 on cell surface. Next we analyzed 
whether this effect is restricted to 2H9 antibody or is a broader phenomena shared among other 
available antibodies and reflecting CD9 aggregation. 
For this purpose we preincubated BMMCs as previous with 2H9 antibody or one of two 
commercially available antibodies against CD9 – KMC8.8 and N-19. As a control, cells were 
preincubated with antibody (anti-CD48) of the same isotype as 2H9 antibody. Cells were then 
activated with TNP-BSA (0.5 µg/ml) for 30 min and extent of degranulation was assessed by β-
glucuronidase assay.  
Fig. 13 – Degranulation of BMMCs preincubated with different antibodies. 
BMMCs were preincubated with 30 µg/ml of anti-CD9 antibodies (2H9, KMC8.8, N-19) and anti-
CD48 (αCD48) antibody. Cells were then activated with 0.5 µg/ml of TNP-BSA (TNP). Extent of 
degranulation was estimated by amount of β-glucuronidase released to supernatant. Data are 
presented as mean ± SD of one experiment performed in triplicate of two similar experiments. 
Statistical significance was determined between non-treated control (TNP) and antibody-treated 
samples. (*, P<0.05) 
Results in Fig. 13 clearly demonstrate that inhibition of degranulation is present even in case 
when other commercially available antibody KMC8.8 is used. As expected, antibody used as 
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isotype control (anti-CD48) did not cause any significant change in extent of degranulation. 
Surprisingly, another commercially available anti-CD9 antibody N-19 did not inflict impairment of 
degranulation response. Therefore we next verified ability of each antibody to bind to their 
appropriate ligand on BMMC surface by flow cytometry analysis. BMMCs were probed with the 
tested antibodies (30 µg/ml), then labeled with 300× diluted secondary anti-rat-IgG-FITC or anti-
goat-IgG-Cy3 and analyzed in FL1 and FL2 channel respectively. 
As it is shown in Fig. 14, all antibodies except N-19 bind to their target protein on surface of 
BMMCs. 
 
Fig. 14 – Verification of ability of antibodies to bind their target structures on BMMCs 
surface. 
Ability of antibodies to bind their target proteins was determined after staining with appropriate 
fluorescent secondary antibody by flow cytometry analysis. Red line represents background 
fluorescence of cells incubated with secondary antibody only. Blue line represents fluorescence of 
cells probed with 2H9 (A), KMC8.8 (B), anti-CD48 (C) and N-19 (D) antibody and stained with 
anti-rat-IgG-FITC (A, B, C) or anti-goat-IgG-Cy3 (D) secondary antibody. 
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5.7.3 Effect of secondary antibody 
Effect of anti-CD9 antibody on antigen-mediated degranulation might be inflicted by different 
mechanisms. One of them may be forced aggregation of otherwise distinctly located CD9 molecules 
by molecule of immunoglobulin. We therefore wanted to verify if this effect can be further 
strengthened by additional clustering with polyclonal antibody against rat IgG immunoglobulins. 
For this purpose BMMCs were first incubated with anti-CD9 antibody (30 µg/ml) for 20 min, 
washed with BSS-BSA and then incubated with anti-rat polyclonal antibody (10 µl/ml) for another 
20 min. Cells were then activated as previous. 
Results of this experiment show that additional aggregation of CD9 by anti-rat polyclonal 
antibody doesn’t have any further effect on extent of BMMCs degranulation. 
 
Fig. 15 – Effect of secondary antibody on 2H9-mediated BMMCs degranulation. 
Cells were preincubated with anti-CD9 antibody (2H9) alone or with anti-CD9 followed by anti-
rat-IgG incubation (2H9+αRat). Cells were then challenged with antigen (TNP-BSA, TNP) and 
amount β-glucuronidase in supernatant was estimated. Data are presented as mean ± SD of one 
experiment performed in triplicate of two similar experiments. (n.s., P>0.05) 
5.7.4 Effect of IgE sensitization 
Previous study concerning effects of anti-CD9 antibody on RBL cells transfected with human 
CD9 reported that these effects originated mainly from binding of anti-CD9 antibody to FcεRI 
receptor and thus cross-linking it to CD9 proteins (Higginbottom et al., 2000b). To exclude this 
possibility, we conducted experiment in which BMMCs were sensitized with different 
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concentrations of IgE and then incubated in mixture of anti-CD9 antibody (30 µg/ml) with 
appropriate concentration of IgE.  Cells were then washed to remove unbound IgE and activated by 
TNP-BSA. 
Result of this experiment suggests that co-clustering of CD9 with FcεRI does not play role in 
anti-CD9-mediated inhibition of degranulation in BMMCs because extent of inhibition was the 
same throughout all IgE concentrations as it may be seen in Fig. 16. 
 
Fig. 16 – Degranulation of BMMCs preincubated with anti-CD9 antibody in the presence of 
various concentrations of IgE. 
Sensitized BMMCs were incubated with mixture of 30 µg/ml 2H9 antibody and the indicated 
concentration of IgE. After brief wash, cells were activated with 0.5 µg/ml of TNP-BSA and extent 
of degranulation was measured by β-glucuronidase assay.  Data are presented as mean ± SD of one 
experiment performed in triplicate of two similar experiments. Statistical significance was 
determined between control amount of IgE (1 µg/ml) and increased concentration of IgE (5, 10, 30 
µg/ml) in presence of 2H9 antibody. (n.s., P>0.05) 
5.8 BMMC degranulation induced by CD9 aggregation 
5.8.1 Comparison with other monoclonal antibodies 
Next we decided to look closer on degranulation elicited by antibody itself (see Fig. 12 at 0 
min). Again, we tested whether this effect is restricted to our 2H9 antibody or it is induced also by 
other anti-CD9 antibodies. The cells were subjected to 30 µg/ml of 2H9, KMC8.8 or anti-CD48 
0
10
20
30
40
50
60
70
80
90
100
1 5 10 30
β
-g
lu
cu
ro
n
id
as
e
 r
e
le
as
e
 (
%
)
IgE  (μg/ml)
- 2H9
+ 2H9
n.s. n.s. n.s.
59 
antibody as isotype control for 30 min and then assayed for a degranulation. N-19 antibody was 
excluded from this experiment due to its inability to bind CD9 on BMMCs (see Fig. 14). 
Fig. 17 shows that BMMCs degranulated in response to KMC8.8 antibody treatment, although 
to lesser extent than in case when 2H9 antibody was used. Degranulation caused by isotype control 
was almost on same level as in non-activated control. 
 
Fig. 17 – Degranulation triggered by anti-CD9 antibodies. 
Non-sensitized cells were incubated for 15 min with 30 µg/ml of various anti-CD9 antibodies (2H9, 
KMC8.8) or anti-CD48 antibody (αCD48) and supernatant was examined for β-glucuronidase 
content. Data are presented as mean ± SD of one experiment performed in triplicate of three 
similar experiments. Statistical significance was determined between non-activated control (NA) 
and antibody-treated samples. (*, P<0.05) 
5.8.2 Concentration dependence 
To estimate relationship between concentration of antibody and rate of degranulation inflicted by 
its binding to CD9, non-sensitized BMMCs were exposed to different concentrations of 2H9 
antibody for 15 min. Supernatant was then immediately assayed using β-glucuronidase assay. 
Data in Fig. 18 show that antibody triggers degranulation at relatively low concentrations (100 
ng/ml) and its maximal effect is at concentration 1 µg/ml after which BMMCs degranulation slowly 
declines. 
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Fig. 18 – Degranulation of BMMCs in response to different concentrations of 2H9. 
Non-sensitized cells were incubated for 15 min with the indicated concentration of 2H9 antibody. 
Extent of degranulation was estimated by amount of β-glucuronidase released to supernatant. Data 
are presented as mean ± SD of one experiment performed in triplicate. 
5.8.3 CD9 and FcεRI co-clustering 
Next, we wanted to know whether this direct effect of anti-CD9 antibody is caused by co-
clustering of FcεRI receptor with CD9. Both sensitized and non-sensitized cells were subjected to 
30 µg/ml of 2H9 antibody for different time intervals. Extent of degranulation was determined by 
presence of β-glucuronidase in supernatant. 
No difference between sensitized and non-sensitized cells was observed as seen in Fig. 19 
suggesting that cross-linking of FcεRI receptor with CD9 does not play role in this process. 
Moreover, kinetics of antibody-mediated degranulation is fast as determined from Fig. 19, since at 
30 s after treatment degranulation almost reaches maximal response. 
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Fig. 19 – Comparison of 2H9-mediated degranulation between sensitized and non-sensitized 
cells. 
Both sensitized and non-sensitized cells were challenged with 30 µg/ml of 2H9 antibody for 
indicated time. At 0 min, no 2H9 antibody was added. Data are presented as mean ± SD of one 
experiment performed in triplicate of two similar experiments. Statistical significance was 
determined between non-sensitized and sensitized cells at each time point. (n.s., P>0.05) 
5.9 Binding of fluorescently labeled TNP-BSA to FcεRI receptor 
One can think of another possibility which could explain inhibition of antigen-mediated 
degranulation by anti-CD9 antibodies. Because CD9 is relatively high abundant on cell surface 
(Hemler, 2005), extensive binding of anti-CD9 antibodies might physically interfere with TNP 
binding to IgE-loaded FcεRI receptor. This could lead to less receptor cross-linking, resulting in 
lesser degree of activation and degranulation. 
In order to exclude this possibility, we decided to determine extent to which TNP-BSA binds to 
sensitized BMMCs when probed with anti-CD9 antibodies. TNP-BSA was fluorescently labeled 
with TRITC (see 4.8) which enabled us to detect its presence on cell surface. Sensitized cells were 
probed with increasing concentration of 2H9 antibody followed by addition of TNP-BSA-TRITC 
(0.5 µg/ml). After washing away unbound TNP-BSA-TRITC, cells were analyzed on LSRII flow 
cytometer using 561 nm excitation, 575/15 filter and 565 low-pass dichroic mirror configuration. 
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Results of this experiment show that TNP-TRITC binds to IgE-loaded FcεRI receptor to the 
same extent regardless of 2H9 concentration used. Furthermore this binding is always identical to 
binding to cells non-treated with 2H9 antibody (Fig. 20). 
 
Fig. 20 – Level of TNP-BSA-TRITC binding to surface of BMMCs pretreated with different 
2H9 concentrations.  
Black line represents background fluorescence of non-sensitized BMMCs incubated with TNP-BSA-
TRITC. In all charts, binding of TNP-BSA-TRITC to sensitized BMMCs is compared between cells 
preincubated with 0 µg/ml of 2H9 antibody (blue line) and cells preincubated with increasing 
concentration of 2H9 antibody (red line) – 1 µg/ml (A), 10 µg/ml (B), 30 µg/ml (C), 60 µg/ml (D). 
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5.10 Calcium release of cells treated with anti-CD9 antibody 
5.10.1 Response induced by TNP and aggregation of CD9 
Results from our experiments revealed that binding of anti-CD9 antibodies to CD9 on BMMCs 
surface causes low-level degranulation. Moreover, if subsequently these cells are activated via 
FcεRI receptor their degranulation response is lower compared to cells non-treated with anti-CD9 
antibodies. One of the key steps in mast cell activation is release of calcium stored in ER to cytosol 
followed by influx of extracellular calcium ions. This rise of intracellular calcium in combination 
with other signaling events then leads to release of secretory granules content (Gilfillan and 
Tkaczyk, 2006). It is therefore essential to examine whether calcium response is also altered in cells 
exposed to anti-CD9 antibodies. 
Sensitized BMMCs were first loaded with Fura-2 which is widely used fluorescent calcium 
reporter dye.  After washing the cells, their calcium response was measured with or without 
pretreatment with 2H9 antibody followed by TNP-BSA. Fig. 21 shows that addition of 2H9 
antibody by itself triggers calcium release which corresponds to previously observed effect on 
degranulation (Fig. 12 at 0 min). After subsequent TNP-BSA addition, calcium response of these 
cells is impaired compared to control cells without earlier 2H9 stimulation which again corresponds 
to previously observed results (Fig. 12 later time points). 
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Fig. 21 – Calcium response after consequent 2H9 and TNP-BSA addition. 
Calcium mobilization of Fura-2 loaded cells was measured on Infinite 200M plate reader. Cells 
were first triggered by 2H9 antibody followed by TNP-BSA triggering. Calcium level is expressed 
as ratio of emission with excitation at 340 nm and 380 nm. Curves represent mean of three 
experiments. 
5.10.2 Effect of antibodies and serum pretreatment on TNP-induced calcium 
response 
Mast cells along with FcεRI receptor express also several types of Fcγ receptors which contains 
activation ITAM or inhibitory ITIM motifs in their cytosolic part and thus can influence mast cell 
activation in either positive or negative way (Tkaczyk et al., 2004). To rule out involvement of 
these receptors in anti-CD9 antibody-mediated effects, BMMCs loaded with Fura-2 were incubated 
with IgG antibodies isolated from normal rat serum to block all Fcγ receptors. Cells were then 
probed with anti-CD9 antibodies or anti-CD48 antibody as isotype control and their calcium levels 
after triggering were measured by TNP-BSA. 
Fig. 22 demonstrates that both 2H9 and KMC8.8 antibodies inhibit antigen-mediated calcium 
response compared to non-treated and isotype controls. These results also suggest that anti-CD9-
mediated inhibition of degranulation and calcium release is not dependent on Fcγ receptors. 
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Fig. 22 – Effect of BMMCs co-incubation with serum IgGs and different antibodies on 
antigen-mediated calcium response. 
Calcium mobilization of Fura-2 loaded cells was measured on Infinite 200M plate reader. Cells 
were first coincubated with normal rat serum IgGs together with anti-CD9 antibodies (2H9, 
KMC8.8) or anti-CD48 antibody (αCD48) and then triggered by TNP-BSA. Calcium level is 
expressed as ratio of emission with excitation at 340 nm and 380 nm. Curves represent mean of 
three experiments. 
5.10.3 Role of CD9 aggregation in ER calcium release and influx of calcium 
To investigate detailed features of intracellular calcium signal in the context of anti-CD9 
antibodies effect, it is necessary to distinguish between initial release of calcium from ER and 
consequent influx of calcium ions from extracellular space. This is possible by activating cells in 
calcium-free environment which prevents entry of extracellular calcium and therefore only ions 
from ER are released to the cytosol. When are ER stores depleted, calcium channels in the plasma 
membrane consisting of Orai subunits became opened due to action of ER calcium sensor STIM 1 
(Vig and Kinet, 2009). Restoring levels of extracellular calcium then leads to immediate influx of 
calcium to cytosol from extracellular space. 
Firstly, we examined antibody-mediated inhibition of calcium response after triggering by TNP-
BSA. Sensitized and Fura-2 loaded cells were either incubated or not with 2H9 antibody for 15 min 
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and then triggered by TNP-BSA in the absence of extracellular calcium. This was followed by 
addition of calcium to restore its level. 
Results reveal that 2H9 antibody-treated cells release calcium from their ER in slightly lower 
extent and, interestingly, this release lags behind one present in non-treated cells. Subsequent 
calcium influx measured after calcium addition was also lower in 2H9-treated cells (Fig. 23). 
 
Fig. 23 – Effect of 2H9 on antigen-mediated calcium release from ER and calcium influx. 
Calcium mobilization of Fura-2 loaded cells was measured on Infinite 200M plate reader. Cells 
were first preincubated with 2H9 antibody and then triggered by TNP-BSA in calcium-free 
environment. Calcium content was then restored to 1.8 mM.  Calcium level is expressed as ratio of 
emission with excitation at 340 nm and 380 nm. Curves represent mean of three experiments. 
Next we analyzed activation of the cells mediated by antibody itself. For this purpose, Fura-2 
loaded cells were challenged or not with 2H9 antibody in the absence of extracellular calcium, 
followed by its addition. Fig. 24 shows that binding of 2H9 antibody to cell surface causes release 
of calcium from intracellular stores with subsequent influx from extracellular space compared to 
background level of control cells. 
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Fig. 24 – 2H9-mediated calcium influx and calcium release from ER. 
Calcium mobilization of Fura-2 loaded cells was measured on Infinite 200M plate reader. Cells 
were first triggered by 2H9 antibody in calcium-free environment followed by calcium addition. 
Calcium level is expressed as ratio of emission with excitation at 340 nm and 380 nm. Curves 
represent mean of three experiments. 
5.10.4 Thapsigargin-induced calcium release 
Results in Fig. 23 demonstrate that 2H9 antibody alters both phases of calcium mobilization. To 
finally distinguish whether antibodies against CD9 modulate first or second part of calcium 
response, we decided to use thapsigargin. Thapsigargin is a drug produced by plant Thapsia 
garganica and acts as a potent inhibitor of Ca2+ ATPase in ER membrane and thus preventing them 
from refueling ER calcium stores. This leads to triggering of calcium influx even when cells are not 
being activated through membrane receptors, which means that all proximal signaling events are 
skipped. 
In this experiment cells were again loaded with Fura-2 and incubated with 2H9 antibody for 15 
min. Intracellular calcium levels were measured after addition of thapsigargin (0.5 µM) in the 
absence of extracellular calcium. Levels of extracellular calcium were restored by its addition. 
Data shown in Fig. 25 demonstrate that both 2H9-treated and non-treated cells release calcium 
after thapsigargin administration to the same extent. This suggests that anti-CD9 antibody act 
upstream or at level of calcium release from ER. 
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Fig. 25 – Effect of 2H9 on thapsigargin-mediated calcium release from ER and calcium influx. 
Calcium mobilization of Fura-2 loaded cells was measured on Infinite 200M plate reader. Cells 
were first preincubated with 2H9 antibody and then triggered by thapsigargin in calcium-free 
environment. Calcium content was then restored to 1.8 mM.  Calcium level is expressed as ratio of 
emission with excitation at 340 nm and 380 nm. Curves represent mean of three experiments. 
Effects of 2H9 antibody on BMMCs degranulation induced by thapsigargin were also tested. 
Cells preincubated with 2H9 antibody were subjected to 0.5 µM thapsigargin for 30 min and the 
extent of degranulation was assessed by β-glucuronidase assay. 
Results of this experiment confirm the results of previous experiment that 2H9 antibody does not 
have effect on activation via thapsigargin route and thus it has to act upstream of calcium response 
(Fig. 26). 
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Fig. 26 – Effect of 2H9 antibody on thapsigargin-induced degranulation of BMMCs. 
BMMCs were preincubated with 30 µg/ml of anti-CD9 antibody (2H9). Cells were then activated 
with 0.5 µg/ml of TNP-BSA (TNP) or 0.5 µM thapsigargin or were left non-activated (NA). Extent 
of degranulation was estimated by amount of β-glucuronidase released to supernatant. Data are 
presented as mean ± SD of one experiment performed in triplicate of three similar experiments. 
Statistical significance was determined between non-treated controls and 2H9-treated samples. (*, 
P<0.05) 
5.11 Phosphorylation time course 
To determine which signaling molecules acting upstream of calcium release might be involved 
in 2H9-mediated effects, sensitized BMMCs were either incubated or not with 2H9 antibody and 
activated for different time with TNP-BSA. Cells were then lysed in lysis buffer B supplemented 
with detergent (1% NP-40 and 1% lauryl maltoside) and an inhibitor of protein tyrosine 
phosphatases sodium orthovanadate. Samples were boiled in non-reducing sample buffer and 
resolved on 10% SDS-PAGE gel. After western blotting, tyrosine phosphorylation was detected by 
probing membrane with anti-phosphotyrosine antibody (PY20) and anti-phosphoPLCγ1 with 
combination. Immunostaining of actin was used as loading control. 
Fig. 27 shows that many proteins including those with molecular weight of LAT, NTAL and 
PLCγ1 are phosphorylated in BMMCs pretreated with 2H9 at 0 min time point. In contrast, all these 
proteins are less phosphorylated at later time points. This however correlates with previously 
obtained results of degranulation and calcium release. 
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Fig. 27 – Differences in tyrosine phosphorylation in BMMCs triggered by antigen caused by 
2H9 antibody pretreatment. 
Sensitized BMMCs preincubated with 30 µg/ml of anti-CD9 antibody (2H9) were compared to cells 
without preincubation (control) at different time of activation by TNP-BSA (30 µg/ml).Whole 
tyrosine phosphorylation was detected by anti-phosphotyrosine (PY20) antibody (5000×). Arrows 
mark bands with molecular weight corresponding to LAT and NTAL proteins. Phosphorylation 
status of PLCγ1 (pPLCγ1) was detected by anti-phosphoPLCγ1 antibody (500×) in combination 
with anti-rabbit-IgG-HRP secondary antibody (10,000×). Actin, which served as loading control, 
was detected by anti-actin antibody (1000×) and anti-mouse-IgG-HRP (10,000×). 
5.12 Analysis of cells with decreased or enhanced CD9 expression 
5.12.1 Generation of CD9 knockdown and overexpressing cells 
Technique of gene silencing is now commonly used method which enables to discover function 
of cellular proteins by analyzing phenotypes resulting from their lowered expression. It is also a 
powerful tool for verifying results obtained by different methods. We therefore proceeded to 
generation of BMMCs with altered levels of CD9 protein – either downregulated (CD9KD) or 
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upregulated (CD9OE). To do so, lentiviral system (Open biosystems) which provides easy and 
stable transfection of primary cells was used. This system is based on infection of cells with 
replication-deficient form of lentivirus carrying gene of interest or sequence for short hairpin 
ribonucleic acid (shRNA) under strong CMV promoter. Vector for CD9 overexpression 
(pCDH/CD9) was constructed by subcloning CD9 cDNA from pYX-Asc vector to lentiviral 
expression vector pCDH. For detailed procedure overview see 4.7 in materials and methods. 
In order to verify effectiveness of overexpression and silencing, intact cells were probed with 
anti-CD9 antibody (2H9; 100×) and fluorescent secondary anti-rat-IgG-FITC antibody (300×) and 
analyzed on flow cytometer. Furthermore, to determine total protein level, cell lysates (lysis buffer 
B supplemented with 1% NP-40 and 1% Lauryl maltoside) were resolved on 12% polyacrylamide 
gel and blotted to nitrocellulose membranes.  Membranes were then probed with 2H9 antibody 
(1000×) and anti-actin antibody (1000×), used as a loading control and then with secondary 
antibodies anti-rat-IgG-HRP (8000×) and anti-mouse-IgG-HRP (10,000×) respectively. 
Fig. 28 shows that the lowest total CD9 expression is in cells infected with vector construct 
TRCN0000066393 (93) while expression in non-silencing control (non-siRNA) remains identical to 
non-infected (NI) cells. It also appears that level of CD9 protein is increased in cells infected with 
pCDH/CD9 vector (CD9OE). Again cells infected with empty pCDH vector (non-OE) contains 
comparable amount of CD9 as NI cells. 
 
Fig. 28 – Expression of CD9 in CD9KD and CD9OE BMMCs. 
BMMCs lysates were separated on 12% SDS-PAGE gel, western blotted and expression of CD9 
was detected by 2H9 antibody and anti-rat-IgG-HRP secondary antibody. Actin was used as a 
loading control. Numbers indicate fold change of CD9 amount over non-infected (NI) control 
normalized to amount of Actin. 
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Considering these results, cells carrying construct 93 were choosen for surface expression 
analysis on flow cytometer. Results in Fig. 29 and Fig. 30 correspond to data shown in Fig.28 and 
thus 93 cells which had lowest CD9 level were selected for later experiments and later on termed as 
CD9KD. 
 
Fig. 29 – Expression of CD9 in CD9KD an CD9OE cells analyzed by flow cytometry. 
BMMCs were incubated with 10 µg/ml of 2H9 antibody and then probed with 300× diluted 
secondary anti-rat-IgG-FITC antibody. Red line represents fluorescence of non-infected (NI) cells 
compared to non-siRNA control cells (A), CD9KD cells (B), non-OE cells (C), CD9OE cells (D) 
and background fluorescence of cells probed by secondary antibody only (E) represented by blue 
line.  
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Fig. 30 – Calculated mean cell fluorescence from flow cytometry profile of CD9 expression. 
Data represents average of geometric mean ± SD of experiments performed in triplicate. 
Background fluorescence (control), non-infected cells (NI), non-siRNA, CD9KD, non-OE and 
CD9OE cells. 
5.12.2 Degranulation of CD9KD and CD9OE cells pretreated with anti-CD9 antibody 
Next step was to prove previously obtained results using CD9KD and CD9OE established cells. 
Again, cells were incubated or not with 2H9 antibody (30 µg/ml) and after 15 min activated by 
addition of TNP-BSA. Degranulation of 2H9-treated cells was calculated as percentage of 
degranulation of corresponding non-treated cells. 
From Fig. 31 is evident that when CD9 expression is downregulated by shRNA (CD9KD), 
antibody-meditated inhibitory effect is significantly reduced. Importantly, in case of CD9OE cells, 
the inhibitory effect was even more pronounced than in WT cells.  
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Fig. 31 – Effect of anti-CD9 antibody on antigen-mediated degranulation of CD9KD and 
CD9OE BMMCs. 
Sensitized BMMCs were preincubated with 30 µg/ml of 2H9 antibody. Cells were then activated 
with 0.5 µg/ml of TNP-BSA. Extent of degranulation was estimated by amount of β-glucuronidase 
released to supernatant. Data are presented as percentage of 2H9-non-treated controls ± SD of two 
experiments performed in triplicate. Statistical significance was determined between CD9KD and 
CD9OE cells and their non-infected controls (non-siRNA, non-OE). (*, P<0.05) 
5.12.3 CD9KD and calcium response 
To support degranulation data, intracellular calcium levels were measured in CD9KD and non-
siRNA control cells after triggering with 2H9 antibody followed by addition of TNP-BSA. Results 
from control experiment shown in Fig. 32 demonstrate that there is no difference in calcium 
response between CD9KD and non-siRNA cells. Surprisingly, this suggests that lowering CD9 
expression does not have any effect on mast cell activation. However, when both these cells are 
triggered with antibody, CD9KD cells exhibit lower calcium response compared to non-siRNA 
control (Fig. 33). Moreover, when subsequently activated with TNP-BSA, CD9KD cells have 
higher response than non-siRNA cells and it almost reaches values observed in control experiment 
(compare Fig. 33 to Fig. 32). 
0
20
40
60
80
100
120
non-siRNA CD9KD non-OE CD9OE
β
-g
lu
cu
ro
n
id
as
e
 r
e
le
as
e
(%
 o
f 
 c
o
n
tr
o
l)
*
*
75 
 
Fig. 32 – Control calcium experiment comparing CD9KD and non-siRNA cells. 
Calcium mobilization of Fura-2 loaded cells was measured on Infinite 200M plate reader. Cells 
were first challenged with BSS-BSA instead 2H9 antibody followed by TNP-BSA triggering. 
Calcium level is expressed as ratio of emission with excitation at 340 nm and 380 nm. Curves 
represent mean of three experiments. 
 
Fig. 33 – Calcium response after 2H9 and TNP-BSA triggering in CD9KD and non-siRNA 
cells. 
Calcium mobilization of Fura-2 loaded cells was measured on Infinite 200M plate reader. Cells 
were first triggered by 2H9 antibody followed by TNP-BSA triggering. Calcium level is expressed 
as ratio of emission with excitation at 340 nm and 380 nm. Curves represent mean of three 
experiments. 
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5.12.4 CD9KD degranulation 
Results in Fig. 34 surprisingly showed that there is almost no difference between CD9KD and 
control cells in calcium release initiated by TNP-BSA triggering. Therefore β-glucuronidase assay 
was performed to verify these results on level of degranulation. Result of this experiment confirmed 
previous one (Fig. 33) that CD9KD cells show no difference in degranulation compared to control 
non-siRNA cells. 
 
Fig. 34 – Comparison of CD9KD and non-siRNA cells antigen-mediated degranulation. 
Sensitized BMMCs were activated with 0.5 µg/ml of TNP-BSA. Extent of degranulation was 
estimated by amount of β-glucuronidase released to supernatant. Data are presented as mean ± SD 
of three experiments performed in triplicate. Statistical significance was determined between 
CD9KD and non-siRNA control. (n.s., P>0.05; n=3) 
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6 Discussion 
Mast cells are known effector cells of the immune system. They have been implicated in such 
important processes as host defense against bacteria, toxins or parasites. However, in some cases 
they can develop improper reaction against harmless environmental antigens and thus causing 
allergies. It is therefore essential to understand signaling events that lead to activation of these cells 
in order to develop new treatment strategies.  
Monoclonal antibodies are unique tools that can be used either for curing allergies as in the case 
of Omalizumab (Winchester et al., 2006) or for identifying new molecules and characterization of 
various protein functions involved in mast cell signal transduction. Our laboratory already 
developed several monoclonal antibodies which were useful in further research of mast cell 
signaling (Hálová et al., 2001, 2002; Smrž et al., 2008). Initial aims of this diploma thesis were to 
characterize properties of an antibody raised against membrane structures of BMMCs which 
showed strong binding affinity to these cells. Next objective was to identify specificity of this 
antibody. 
To this end we found that 2H9 antibody strongly reacts with its binding partner on the surface of 
BMMCs and can be used for detection of the antigen by flow cytometry, western blot 
immunodetection and immunoprecipitation. We therefore decided to proceed to identification of 
target protein. The most used strategies for identification of unknown proteins are Edman 
degradation and MS. However, classical method of Edman degradation holds many drawbacks such 
as necessity of high amount and purity of protein, low accuracy and problems with glycosylated 
proteins. On the other hand, modern method of MS analysis efficiently eliminates these problems 
by its higher sensitivity and thus low amount of protein is needed and glycosylations do not cause 
any problem. Taking all these considerations into account, we decided to isolate the antigen by 
immunoaffinity purification followed by MS analysis. Because binding of rat IgG1 antibody isotype 
to protein A is limited, immobilized protein G was used instead and in order to eliminate 
contamination from similarly large Ig light chain, 2H9 antibody was covalently coupled to protein 
G by DMP. Using this optimized purification procedure, the target protein was successfully purified 
and identified by MS as CD9. 
The antibody specificity was supported by other results which correspond to what is known 
about CD9. It was shown that CD9 is not a GPI-anchored protein but integral four times spanning 
membrane protein (Boucheix et al., 1991) and it has broad tissue distribution (Sincock et al., 1997). 
Final proof for CD9 identity came from cross-immunoprecipitation with 2H9 and commercial 
antibody KMC8.8.  
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Protein CD9 is one of the most studied members of tetraspanin superfamily. Its structure 
comprises of two short cytoplasmic tails, four transmembrane domains and small and large 
extracellular loops. LEL is known to contain two disulphide bridges which stabilize its 
conformation (Seigneuret et al., 2001). Decrease in detection efficiency of reduced CD9 by 
immunodetection with 2H9 antibody suggests that antibody probably recognizes conformational 
epitope on LEL which is destroyed after disulphide bond breakage. Research in past two decades 
revealed implication of CD9 in many processes such as cellular fusion, motility, adhesion and 
survival. Considerable amount of interest was dedicated to research of role of CD9 in hematopoietic 
cells. Anti-CD9 antibodies were shown to activate platelets (Ozaki et al., 1995), macrophages (Kaji 
et al., 2001) and eosinophils (Kim et al., 1997) even though these effects were Fc receptor 
dependent. Furthermore, antibodies against CD9 (Higginbottom et al., 2000b) and other tetraspanin 
proteins CD63 (Kraft et al., 2005) and CD81 (Fleming et al., 1997) were indispensable for 
uncovering roles of these tetraspanins in mast cell signaling and physiology. Previous study 
describing effects of anti-CD9 antibody on activation of mast cells was dealing only with effects on 
RBL cell line but no reports on mouse mast cells (e.g. BMMCs) were published up to now. This 
encouraged us to take closer look on function of this protein in BMMCs using our anti-CD9 
antibody (2H9). 
Initial experiments with BMMCs exposed to 2H9 antibody showed interesting results. Antibody 
alone stimulated degranulation of these cells, supporting the results of previous study with RBL 
cells (Higginbottom et al., 2000b).Subsequent activation of these cells via FcεRI triggering by TNP-
BSA resulted in lower extent of degranulation which more resembled effects of antibodies against 
CD81 and CD63 (Fleming et al., 1997; Kraft et al., 2005). Moreover, these effects seem to be, 
consistently with previous studies, concentration dependent. These actions could be inflicted by 
various mechanisms such as masking interaction epitope for CD9 interaction partner molecule by 
2H9 antibody or forced aggregation of CD9 proteins by molecule of immunoglobulin which might 
cause alterations in TEMs composition or organization. Results of experiment where CD9 was 
additionally crosslinked by anti-rat secondary antibody did not show any significant enhancement 
of 2H9-mediated inhibition of degranulation. This might be explained by the hypothesis that the 
effect is not caused by forced aggregation but rather by competing with endogenous interaction 
partner of CD9. However, another possibility still remains that 2H9-mediated dimerization of CD9 
already present in dimers (Kovalenko et al., 2004) might be sufficient to disrupt TEMs composition. 
Another possibility is that 2H9 antibody bound to CD9 could sterically block access of TNP-
BSA to FcεRI receptor and thus cause cells to become less activated. Experiments with 
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fluorescently labeled TNP-BSA showed that its binding to IgE-primed Fc receptor is the same, 
regardless of 2H9 concentration used for BMMCs preincubation. This proves that steric blocking of 
antigen binding is not responsible for 2H9-mediated inhibition of degranulation. Previous study 
dealing with RBL cells activation by anti-CD9 antibody concluded that this effect was caused by 
crosslinking of CD9 with FcεRI receptor via anti-CD9 antibody itself (Higginbottom et al., 2000b). 
To test the possibility that 2H9 antibody interacts through its Fc portion with FcεRI and thus 
crosslinks it to CD9, sensitized and non-sensitized BMMCs were treated with 2H9 antibody and 
also cells were treated with mixture of 2H9 and high concentration IgE to compete for 2H9 binding 
to FcεRI receptor. In both cases 2H9-mediated activation and inhibition of degranulation 
respectively were preserved. Another possibility could be that 2H9 antibody acts through binding to 
Fcγ receptor as was described in case of platelets or macrophages (Griffith et al., 1991; Kaji et al., 
2001). Mast cells were also shown to possess different Fcγ receptors on their surface which can 
provide either activatory or inhibitory signals and thus could be responsible for 2H9-mediated 
activities. However, experiments with cells preincubated with excess of normal rat serum IgG 
antibodies excluded this possibility. Thus it seems that none of these mechanisms are responsible 
for the observed 2H9-mediated activities. 
As mentioned before, various anti-CD9 antibodies were reported to have either activatory or 
inhibitory effects on mast cell degranulation. Testing two different commercially available anti-
CD9 antibodies KMC8.8 and N-19 showed that KMC8.8 has similar effect on mast cell activation 
as 2H9 antibody. Surprisingly, N-19 did not inflict any change in mast cell degranulation but test 
for binding ability showed that this antibody is not able to bind CD9 on surface of BMMCs. Control 
antibody, specific for CD48 protein, was able to bind to its target molecule but did not alter mast 
cell response. This means that 2H9 in not the only anti-CD9 antibody capable to interfere with 
activation of mast cells. In contrast, other antibodies of the same isotype but specific for other 
surface protein were inefficient.  
Mast cell signaling pathways converge at release of Ca2+ from ER to cytosol. When ER stores 
are depleted, calcium sensor STIM1 clusters and moves to regions of ER which are close to plasma 
membrane where it activates calcium channels consisting of Orai1 subunits. This results in calcium 
influx and more increase of cytosolic calcium level (Vig and Kinet, 2009). Calcium is known to 
activate PKC and both together act as master regulators of mast cell secretory granules exocytosis 
(Gilfillan and Tkaczyk, 2006). Experiments showed that alterations in calcium response are 
responsible for both 2H9-mediated BMMCs activation and inhibition of degranulation via FcεRI 
aggregation. Binding of 2H9 antibody to BMMCs caused transient peak of intracellular calcium 
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level. When these cells were activated via TNP-BSA, the calcium response was generally lower 
than in cells which were not pretreated with 2H9 antibody. Similar mechanism was also observed 
for another anti-CD9 antibody, KMC8.8. These experiments mapped only overall change in 
cytosolic calcium. However, anti-CD9 antibodies might potentially act at two different points of 
this signaling event: (1) at the level of calcium release from ER and (2) at the level of extracellular 
calcium influx. Results revealed that BMMCs pretreated with 2H9 antibody exhibited slightly lower 
calcium release from ER, the initiation of which was also markedly shifted to the later time. 
Subsequent calcium influx was also impaired under these conditions. When BMMCs were activated 
via inhibitor of ER Ca2+ ATPases thapsigargin, which leads to accumulation of calcium in cytosol 
without activation of proximal signaling, 2H9-pretreated BMMCs degranulated with the same 
extent and their intracellular calcium level was identical to control cells non-treated with antibody. 
This suggests that 2H9 antibody does not interfere with calcium influx machinery (for example by 
blocking Orai1 channels) but rather acts upstream or at the level of calcium release from ER. 
Taking all these results together it is possible to propose hypothesis that the initial calcium release 
caused by 2H9 antibody binding is responsible for subsequent lower and delayed calcium release 
from ER and thus also impaired calcium influx. 
To determine which signaling proteins acting upstream of calcium release are involved in anti-
CD9-mediated processes, phosphorylation status of cellular proteins was examined. The results 
showed that the level of tyrosine phosphorylation of proteins with molecular weight of LAT, NTAL 
and PLCγ1, is increased in 2H9-activated BMMCs in the absence of antigen exposure. In contrast, 
pretreatment with 2H9 antibody decreased phosphorylation of all these proteins in cells activated by 
antigen. This correlates with the results on the effect of 2H9 on degranulation and calcium release. 
Mechanism of the observed 2H9-induced phosphorylation might involve activation of Scr family 
kinases Lyn or Fyn or as previously described activation of Syk kinase (Ozaki et al., 1995). 
However, in their case Syk kinase activation was coupled with CD9 and Fc receptor crosslinking 
and this scenario was excluded by our experiments. Final proof require performing experiments in 
which the cells will be activated with F(ab)2 fragments of 2H9 antibody which lack Fc portion 
responsible for association with Fc receptors. 
To verify effects of 2H9 antibody on BMMCs, stabile BMMC transfectants with decreased 
(CD9KD) or increased (CD9OE) levels of CD9 were generated using lentiviral transfection system. 
Experiments on these cells confirmed involvement of CD9 protein in before-mentioned effects of 
2H9 antibody. CD9KD cells showed substantially less inhibition of degranulation and calcium 
release caused by 2H9 binding while inhibition of degranulation in case of CD9OE was more 
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prominent. Unexpectedly, degranulation of CD9KD triggered by TNP-BSA remained unchanged 
compared to WT cells. This might be explained by the fact that remaining endogenous CD9 (~10%, 
see Fig. 28) could be sufficient to maintain its activity. However this is most probably not the case 
because if remaining CD9 is sufficient for maintaining its activity, then 2H9 antibody would trigger 
same inhibition of antigen-mediated degranulation and calcium release as WT cells. More probable 
seems hypothesis that lack of CD9 in CD9KD cells is compensated by another tetraspanin localized 
in TEMs. One of possible tetraspanins responsible for this potential compensation might be CD81. 
Reasons for this are that CD81 is structurally similar to CD9 (Seigneuret et al., 2001), effects of 
anti-CD81 antibody were similar to those observed with 2H9 antibody (Fleming et al., 1997) and, 
importantly, CD81 KO mice were shown to have similar phenotype as CD9 KO mice and CD9 and 
CD81 double-KO mice have even more severe phenotype than single-KO mice (Kaji et al., 2002; 
Rubinstein et al., 2006; Takeda et al., 2008). It will be therefore advantageous to examine 
physiological aspects of mast cells generated from CD9 and CD81 double-KO mouse or produce 
cells with concurrently silenced expression of both CD9 and CD81 tetraspanins. 
Monoclonal antibody 2H9 can be widely used for identification and characterization of mouse 
CD9. Its useful properties predict that the antibody can be used for commercial purposes. To this 
end, the antibody was transferred, based on Institutional agreement, to company Exbio, a.s. 
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7 Summary 
Results of this diploma thesis led to these conclusions: 
 Characterization of new rat monoclonal antibody 2H9, raised against BMMCs, showed 
that this antibody is of IgG1 subtype and is suitable for use in flow cytometry, 
immunodetection by western blots and immunoprecipitation. 
 Using of our optimized procedure for immunoaffine isolation combined with MS 
analysis led to identification of 2H9 antibody target protein as member of tetraspanin 
family CD9. This was also supported by comparison with commercially available anti-
CD9 antibodies. 
 Upon its binding to CD9 on the cell surface, 2H9 antibody was shown to initiate 
BMMCs degranulation and at the same time inhibited antigen-mediated degranulation of 
these cells. These effects were not caused by blocking access of antigen to FcεRI, 
coupling of CD9 to FcεRI by 2H9 antibody nor by acting through Fcγ receptors. 
 Examining signaling steps leading to mast cell degranulation revealed that 2H9-induced 
degranulation and inhibition of antigen-mediated signaling reflected changes in calcium 
response.  Moreover, anti-CD9 antibody acted upstream of calcium release from ER 
because thapsigargin-mediated activation remained unchanged and phosphorylation 
state of proteins playing role in FcεRI receptor proximal signaling (e.g. LAT, NTAL and 
PLCγ1) was altered in cells pretreated with 2H9 antibody.  
 Newly generated cells with decreased (CD9KD) or increased (CD9OE) levels of CD9 
showed, respectively less and more pronounced effects mediated by anti-CD9 antibody, 
supporting the role of CD9 in these processes. However, degranulation of CD9KD cells 
was comparable to wild-type cells which is probably the result of compensation by other 
tetraspanin family member. 
 In summary, protein CD9 plays dual role in regulation of mast cell signalization. CD9 
could act as a negative regulator of mast cell activation. However, this ability is 
compromised by binding of anti-CD9 antibody which probably competes with unknown 
interaction partner of CD9 or disrupts TEMs composition by aggregating CD9 
molecules. This somehow leads to activation of protein tyrosine kinases and low-level 
degranulation. However, this might also activate negative feed-back mechanisms which 
then dampen signalization after antigen-mediated activation resulting in lower extent of 
degranulation. 
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